WO2004080457A1 - Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them - Google Patents

Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them Download PDF

Info

Publication number
WO2004080457A1
WO2004080457A1 PCT/EP2004/050237 EP2004050237W WO2004080457A1 WO 2004080457 A1 WO2004080457 A1 WO 2004080457A1 EP 2004050237 W EP2004050237 W EP 2004050237W WO 2004080457 A1 WO2004080457 A1 WO 2004080457A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazole
benzamido
pyrimidin
dihydropyrrolo
formula
Prior art date
Application number
PCT/EP2004/050237
Other languages
French (fr)
Inventor
Francesca Abrate
Daniele Fancelli
Mario Varasi
Manuela Villa
Original Assignee
Pharmacia Italia S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia S.P.A. filed Critical Pharmacia Italia S.P.A.
Priority to US10/548,332 priority Critical patent/US20070037790A1/en
Priority to MXPA05009719A priority patent/MXPA05009719A/en
Priority to EP04716253A priority patent/EP1608364A1/en
Priority to BRPI0408486-1A priority patent/BRPI0408486A/en
Priority to JP2006505439A priority patent/JP2006519816A/en
Priority to CA002518395A priority patent/CA2518395A1/en
Publication of WO2004080457A1 publication Critical patent/WO2004080457A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to bicyclo-pyrazole derivatives active as kinase inhibitors and, more in particular, it relates to pyrrolo-pyrazole derivatives, to a process for their preparation, to pharmaceutical compositions comprising them and to their use as therapeutic agents, particularly in the treatment of diseases linked to disregulated protein kinases.
  • the disregulation of protein kinases (PK) activity is the hallmark of numerous diseases. A large share of the oncogenes and proto-oncogenes involved in human cancers code for PKs.
  • PKs are also implicated in many non-malignant diseases, such as benign prostate hyperplasia, femilial adenomatosis, polyposis, neuro- fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis.
  • PKs are also implicated in inflammatory conditions and in the multiplication of viruses and parasites. PKs may also play a major role in the pathogenesis and development of neurodegenerative disorders. For a general reference to PKs malfunctioning or disregulation see, for instance, Current Opinion in Chemical Biology 1999, 3, 459 - 465.
  • the present inventors have now discovered that some pyrrolo-pyrazole derivatives are endowed with multiple protein kinase inhibiting activity and are thus useful in therapy in the treatment of diseases associated with disregulated protein kinases. More specifically, the compounds of this invention are useful in the treatment of a variety of cancers including, but not limited to: carcinoma such as bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hemat ⁇ poietic tumors of lymphoid lineage, including leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgldn's lymphoma, non-Hodgldn's lymphoma, hairy cell lymphoma and Burkett's lymphoma; hema
  • these pyrrolo- pyrazole derivatives are also useful in the treatment of a variety of cell proliferative disorders such as, for instance, benign prostate hyperplasia, femilial adenomatosis, polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis.
  • the compounds ofthe invention can be useful in the treatment of Alzheimer's disease, as suggested by the feet that cdk5 is involved in the phosphorylation of tau protein (J. Biochem., 117, 741-749, 1995).
  • the compounds of this invention may also be useful in the treatment of cancer, viral infections, prevention of ADDS development in HIV-infected individuals, autoimmune diseases and neurodegenerative disorders.
  • the compounds of this invention may be useful in inhibiting tumor angiogenesis and metastasis, as well as in the treatment of organ transplant rejection and host versus graft disease.
  • the compounds of the invention may also act as inhibitor of other protein kinases, e.g., protein kinase C in different isoforms, Met, PAK-4, P ⁇ K-5, ZC-1, STLK-2, DDR-2, Aurora 1, Aurora 2, Bub-1, PLK, Chkl, Chk2, HER2, rafl, MEK1, MAPK, EGF-R, PDGF-R, FGF-R, IGF-R, PI3K, weel kinase, Src, ⁇ bl, Akt, MAPK, ILK, MK-2, IKK-2, Cdc7, Nek, and thus be effective in the treatment of diseases associated with other protein Idnases.
  • protein kinase C in different isoforms Met, PAK-4, P ⁇ K-5, ZC-1, STLK-2, DDR-2, Aurora 1, Aurora 2, Bub-1, PLK, Chkl, Chk2, HER2, rafl, MEK1, MAPK, E
  • the compounds of the invention are also useful in the treatment and prevention of radiotherapy-induced or chemotherapy-induced alopecia.
  • Several heterocyclic compounds are known in the art as protein Idnase inhibitors.
  • heterocyclic urea derivatives disclosed in WO 99/32455 as R ⁇ F Idnase inhibitors
  • aminopyrazole derivatives disclosed in WO 97/40019 as selective protein tyrosine kinase inhibitors.
  • Amino-pyrimidine compounds are disclosed as p38 kinase inhibitors in WO 03/02544.
  • 2-carboxamido- and 2-ureido-pyrazole compounds have been disclosed as protein kinase inhibitors in the international patent applications WO 01/12189, WO
  • Fused bicyclic compounds comprising pyrazole moieties and possessing kinase inhibitory activity have been also disclosed in WO 00/69846 and WO 02/12242, both in the name ofthe applicant itself.
  • the present invention provides a method for treating diseases caused by and/or associated with an altered protein kinase activity, by administering to a mammal in need thereof an effective amount of a pyrazole represented by formula (I)
  • Ri is an optionally substituted 5 or 6 membered heterocyclic group with from 1 to 3 heteroatoms or heteroatomic groups selected from N, NR', O or S, optionally benzocondensed;
  • R 2 is hydrogen or it is selected from the group consisting of R', -COR.', -COOR', -CONR'R" or -S(0) q R';
  • R and 4 are both hydrogen atoms or methyl groups or, together with the carbon atom to which they are attached, form a cyclopropyl group
  • R' and R" are, the same or different and independently in each ofthe above occasions, a hydrogen atom or an optionally substituted group selected from straight or branched Cj-C ⁇ alkyl, C3-C6 cycloalkyl, aryl, aryl Ci-C ⁇ alkyl, heterocyclyl or heterocyclyl Ci-C ⁇ alkyl; m and n are 0 or 1, provided that they are not both 1; q is 0 or an integer from 1 to 2; and the pharmaceutically acceptable salts thereof.
  • the disease caused by and/or associated with an altered protein kinase activity is selected from the group consisting of cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.
  • cancers include carcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system, melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid foUicular cancer and Kaposi's sarcoma.
  • the cell proliferative disorder is selected from the group consisting of benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post- surgical stenosis and restenosis.
  • the method object ofthe present invention also provides tumor angiogenesis and metastasis inhibition.
  • the present invention ftirther provides a pyrazole represented by formula (I)
  • R is a hydrogen atom or a group selected from -COR', -COOR', -CONHR',
  • Ri is an optionally substituted 5 or 6 membered heterocyclic group with from 1 to 3 heteroatoms or heteroatomic groups selected from N, NR', O or S, optionally benzocondensed;
  • R 2 is hydrogen or it is selected from the group consisting of R', -COR', -COOR',
  • R 3 and R are both hydrogen atoms or methyl groups or, together with the carbon atom to which they are attached, form a cyclopropyl group;
  • R' and R" are, the same or different and independently in each ofthe above occasions, a hydrogen atom or an optionally substituted group selected from straight or branched
  • C ⁇ -C 6 alkyl C 3 -C 6 cycloalkyl, aryl, aryl C ⁇ -C 6 alkyl, heterocyclyl or heterocyclyl C ⁇ -C 6 alkyl; m and n are 0 or 1, provided that they are not both 1; q is 0 or an integer from 1 to 2; and the pharmaceutically acceptable salts thereof.
  • the compounds of formula (I), object of the present invention may have asymmetric carbon atoms and may therefore exist either as racemic admixtures or as individual optical isomers.
  • Ci-C ⁇ alkyl we intend a group such as, for instance, methyl, ethyl, n-propyl, isopropyl, n- butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl and the like.
  • C 3 -C 6 cycloalkyl we intend a group such as, for instance, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • aryl we intend a mono- or bi- either carbccyclic as well as heterocyclic group with from 1 to 2 ring moieties, either fused or linked to each other by single bonds, wherein at least one ofthe carbocyclic or heterocyclic rings is aromatic.
  • Non limiting examples of aryl groups are, for instance, phenyl, indanyl, biphenyl, ⁇ - or ⁇ -naphthyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,3,5-triazinyl, indolyl, imidazolyl, inmidazopyridyl, 1,2-methylenedioxyphenyl, thiazolyl, isothiazolyl, pyrrolyl, pyrrolyl-phenyl, furyl, phenyl-furyl, benzotetrahydrofuranyl, oxazolyl, isoxazolyl, pyrazolyl, chromenyl, thienyl, benzothienyl, isoindolinyl, benzoimidazolyl, benzoxazolyl, benzothiazolyl, isoindolinyl-phenyl, quinolinyl, is
  • 5 or 6 membered heterocycle hence encompassing aromatic heterocyclic groups also referred to as aryl groups
  • aryl groups we further intend a saturated or partially unsaturated 5 or 6 membered carbocycle wherein one or more carbon atoms are replaced by 1 to 3 heteroatoms or heteroatomic groups such as N, NR', O or S, wherein R' is as defined in the general formula.
  • Additional examples of 5 or 6 membered heterocyclic groups optionally benzocondensed or further substituted, besides those previously referred to as aryl groups, are 1,3- dioxolane, pyran, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, pyrazoline, piperidine, piperazine, morpholine, tetrahydrofuran, and the like.
  • halogen atom we intend a fluorine, chlorine, bromine or iodine atom.
  • polyfluorinated alkyl we intend a straight or branched Ci-C ⁇ alkyl group as above defined, wherein more than one hydrogen atom is replaced by fluorine atoms.
  • Example of polyfluorinated alkyl groups are, for instance, trifiuoromethyl, 2,2,2- trifluoroethyl, 1,2-difluoroethyl, l,l,l,3,3,3-hexafluoropropyl-2-yl and the like.
  • alkenyl or alkynyl we intend a straight or branched unsaturated hydrocarbon chain having a double or triple bond, with from 2 to 6 carbon atoms such as, for instance, vinyl, ethynyl, 1 -propenyl, allyl, 1- or 2-propynyl, 1-, 2- or 3 -butenyl, 1-, 2- or 3-butynyl, pentenyl, pentynyl, hexenyl, hexynyl and the like.
  • any group which name has been identified as a composite name such as, for instance, cycloalkylalkyl, arylalkyl, heterocyclylalkyl, alkoxy, alkylthio, aryloxy, arylalkoxy, heterocyclyloxy, heterocyclylalkoxy, alkylcarbonyloxy and the like, have to be intended as conventionally construed from the parts to which they derive.
  • heterocyclyl-alkyl stands for an alkyl group being further substituted by a heterocyclyl group, wherein alkyl and heterocyclyl are as above defined.
  • Pharmaceutically acceptable salts of the compounds of formula (I) are the acid addition salts with inorganic or organic acids, e.g.
  • alkali or alkaline-earth metals especially sodium, potassium, calcium or magnesium hydroxides, carbonates or bicarbonates, acyclic or cyclic amines, preferably methylamine, ethylamine, diethylamine, triethylamine or piperidine.
  • a first class of preferred compounds ofthe invention is represented by the derivatives of formula (I) wherein R 2 is hydrogen or a group -COOR', wherein R' is a straight or branched C ⁇ -C 6 alkyl group.
  • Another class of preferred compounds ofthe invention is represented by the derivatives of formula (T) wherein Ri is an optionally substituted heterocycle selected from pyrimidine, thiazole or benzothiazole.
  • Ri is a pyrimidine ring optionally substituted by one or more groups selected from halogen, heterocycles, alkylheterocycles, hydroxyalkylheterocycles, alkoxy, heterocyclyloxy, alkylheterocyclyloxy, alkylthio, alkylsulfonyl, alkylamino, cycloaUcylamino, aiylamino and arylallcylamino, wherein heterocyclyl, allsyl, cycloallcyl and aryl are as above defined. Still more preferred, in any one of the above classes, are the derivatives of formula (I) wherein m is 0 or 1 and n is 0.
  • the compounds of formula (I) and the pharmaceutically acceptable salts thereof may be prepared by a process comprising: a) reacting under acidic or basic conditions a compound of formula (II)
  • R 3 , , m and n are as defined in formula (I), Q represents a suitable nitrogen protecting group and Q' represents R 2 or a suitable nitrogen protecting group; so as to obtain a compound of formula (UT)
  • step (a) of the process the compound of formula (II) is treated under acidic or basic conditions, in the presence of a suitable solvent, for instance dichloromethane or 1,4-dioxane, at room temperature, so as to get the compound of formula (III).
  • a suitable solvent for instance dichloromethane or 1,4-dioxane
  • Q represents the group tert- butoxycarbonyl (boc) whereas Q' is a hydrogen atom or a group R 2 of formula -COOR' wherein R' is lower alkyl, for instance ethyl.
  • the compound of formula (II) may be treated under acidic conditions, for instance in the presence of trifluoroacetic or hydrochloric acid, so as get cleavage ofthe Q group to the corresponding compound of formula (UI).
  • the compound of formula (III) will be in the form of an addition salt, e.g. as a trifluoroacetate or chloridrate salt
  • step (b) ofthe process the compound of formula (IU) is then reacted with a suitable derivative of formula (TV) so as to get the compound of formula (V).
  • the reaction is carried out under basic conditions, for instance in the presence of a suitable alkali carbonate, e.g. potassium carbonate, or of a tertiary base, e.g. diisopropylethylamine.
  • a suitable solvent such as dimethylsulfoxide (DMSO), dimethylformamide, acetonitrile, isopropanol or n-butanol, at a temperature ranging from room temperature to refluxing temperature.
  • DMSO dimethylsulfoxide
  • acetonitrile acetonitrile
  • isopropanol or n-butanol at a temperature ranging from room temperature to refluxing temperature.
  • X represents a chlorine atom or a suitable leaving group such as an alkylsulfonyl or arylsulfonyl group.
  • step (c) of the process the compound of formula (V) is then reacted with any one of the alternative compounds of formula from (VI) to (XI), so as to get the corresponding compound of formula (I) being properly f ⁇ nctionalized at the amino position.
  • the compound of formula (V) by reacting the compound of formula (V): with a derivative of formula (VI), compounds having R as a -COR' group may be obtained; with a derivative of formula (VD), compounds having R as a -COOR' group may be obtained; with a derivative of formula (VIII), compounds having R as a - CONHR' group may be obtained; with a derivative of formula (IX), compounds having R as a
  • the compounds of formula (I) thus obtained may be then converted, according to step (d) ofthe process, in a variety of other compounds of formula (I) ofthe invention, and/or into pharmaceutically acceptable salts thereof, by working according to conventional methods.
  • the compounds of formula (I) wherein Q' stands for a nitrogen protecting group may be easily deprotected according to known methods, for instance under acidic or basic conditions as the case may be, so as to obtain the corresponding compounds wherein R 2 stands for hydrogen; their subsequent functionaUzation at the pyrazole nitrogen atom may then allow to insert any desired R 2 group.
  • carboxy groups may be converted into a variety of derivatives including esters and amides; carboxamides may undergo reduction to amino derivatives; alkylthio groups may be oxidized to alkylsulfinyl or alkylsulfonyl groups or even replaced by amino or alkoxy groups and derivatives thereof; chlorine atoms may be replaced by amino or alkoxy groups and derivatives thereof; nitro groups can be reduced to amines; amines may be further acylated to carboxamides, and the like.
  • step (1) in fact, the compound of formula (II) is first reacted so as to get the desired amino derivative (-NHR) as per previous step (c); in step (2), the intermediate thus obtained is deprotected at the non-pyrazole nitrogen atom and subsequently reacted with a compound of formula (IV), as per previous step (b); finally, in step (3), the obtained compound is further converted into the derivative of formula (I) as per previous step (d).
  • step (1) in fact, the compound of formula (II) is first reacted so as to get the desired amino derivative (-NHR) as per previous step (c); in step (2), the intermediate thus obtained is deprotected at the non-pyrazole nitrogen atom and subsequently reacted with a compound of formula (IV), as per previous step (b); finally, in step (3), the obtained compound is further converted into the derivative of formula (I) as per previous step (d).
  • the compounds of formula (I) of the invention may be also prepared under solid-phase-synthesis (SPS) conditions, which are typicaUy adopted when preparing libraries of compounds according to combinatorial chemistry techniques. Therefore, it is a further object of the invention, a process for preparing the compounds of formula (I) of the invention which comprises: e) hydrolyzing under acidic or basic conditions the compound of formula (I) being obtained in previous step (c) wherein R, Rj, R 3 , R 4 , m and n have the above reported meanings and Q' is a suitable pyrazole nitrogen protecting group
  • step (e) of the process the compound of formula (I) being obtained in step
  • (c) is first deprotected at the pyrazole nitrogen atoms according to conventional means, for instance under acidic or basic hydrolysis conditions.
  • the obtained derivative is then conveniently anchored to an inert polymeric support (P) such as, for instance, 2-chloro-trityl chloride resin, trityl chloride resin, p-nitrophenyl carbonate Wang resin, or an isocyanate polystyrenic resin, which are all conventionally known in this field.
  • P inert polymeric support
  • the cleavage of the Q' group may occur under basic conditions and in the presence ofthe polymeric resin, so as to allow loading ofthe pyrazole intermediate onto the solid phase.
  • the reaction may be carried out in the presence of a slight excess of a suitable base, for instance an amine such as diisopropylethylamine (DIPEA), triethylamine (TEA), 1,8- diazabiciclo[5.4.0]undec-7-ene (DBU) or 2-tert-butyUm__no-2-die1hylamino-l,3- dimethyl ⁇ erhydro-l,3,2-diaza- ⁇ hosphorine, in a suitable solvent such as, for instance, dichloromethane, chloroform, methanol, tetrahydrofuran, dimethylformamide, dimethylacetamide, and the like.
  • a suitable base for instance an amine such as diisopropylethylamine (DIPEA), triethylamine (TEA), 1,8- diazabiciclo[5.4.0]undec-7-ene (DBU) or 2-tert-butyUm__no-2-die1hyla
  • the reaction may be performed by adding to a suspension o the resin, the base and the compound of formula (I) to be supported, under stirring and at a temperature ranging from room temperature to about 55°C for a suitable time, for instance up to 96 hours.
  • the polymer supported compound of formula (XII) thus obtained may be reacted, in step (f), so as to give rise to a variety of derivatives, substantially as set forth above in step
  • step (g) the compound of formula (XII) is cleaved from the resin to which it is supported; resin cleavage may be carried out, for instance, in the presence of trifluoroacetic acid so as to yield the desired compound of formula (I).
  • the compound of formula (XII) is thus suspended in a solution of 5-95% of trifluoroacetic acid in dichloromethane, and the mixture is stirred at room temperature for a suitable time, for instance from a few minutes to about 3 hours.
  • resin cleavage may be also carried out under basic conditions, for instance in the presence of aqueous potassium or sodium hydroxide and in the presence of a suitable co-solvent such as methanol, ethanol, dimethylformamide, 1,4-dioxane or acetonitrile, so as to yield the desired compound of formula (1).
  • a suitable co-solvent such as methanol, ethanol, dimethylformamide, 1,4-dioxane or acetonitrile, so as to yield the desired compound of formula (1).
  • the compound of formula (XII) is thus suspended in a solution of 35% of sodium or potassium hydroxide, for instance in methanol, by worldng under mild operative conditions at temperatures ranging from about 5°C to about 60°C and for a time varying from about 2 hours to about 7 days.
  • the compounds of formula (I) may be conveniently prepared according to paraUel synthesis or combinatorial chemistry techniques widely known in the art, by accomplishing the aforementioned reactions between the several intermediates in a serial manner and by working under SPS (Solid Phase Synthesis) or Solution Phase
  • R is a hydrogen atom or a group selected from -COR', -COOR', -CO HR',
  • Ri is an optionally substituted 5 or 6 membered heterocyclic group with from 1 to 3 heteroatoms or heteroatomic groups selected from N, NR', O or S, optionally benzocondensed;
  • R 2 is hydrogen or it is selected from the group consisting of R', -COR', -COOR',
  • R 3 and R are both hydrogen atoms or methyl groups or, together with the carbon atom to which they are attached, form a cyclopropyl group;
  • R' and R" are, the same or different and independently in each ofthe above occasions, a hydrogen atom or an optionally substituted group selected from straight or branched
  • the compounds of formula (I) are active as protein Idnase inhibitors and are therefore useful, for instance, to restrict the unregulated proliferation of tumor cells. In therapy, they may be used in the treatment of various tumors, such as those formerly reported, as well as in the treatment of other cell proliferative disorders such as psoriasis, vascular smooth ceU proliferation associated with atherosclerosis and post-surgical stenosis and restenosis and in the treatment of Alzheimer's disease.
  • the inhibiting activity of putative Cdk/Cyclin inhibitors and the potency of selected compounds is determined through a method of assay based on the use of the SPA technology (Amersham Pharmacia Biotech).
  • the assay consists of the transfer of radioactivity labelled phosphate moiety by the kinase to a biotinylated substrate.
  • the resulting 33P-labeUed biotinylated product is aUowed to bind to streptavidin-coated SPA beads (biotin capacity 130 pmol/mg), and light emitted is measured in a scintillation counter.
  • the selected compounds are characterized on a panel of ser/threo kinases strictly related to cell cycle (Cdk2/Cyclin E, Cdkl/cyclin BI, Cdk5/p25, Cdk4/Cyclin DI), and also for specificity on MAPK, PKA, EGFR, IGF1-R, Aurora-2 and Akt.
  • the inhibition assay of Cdk5/p25 activity was performed according to the foUowing protocol.
  • ATP 0.3 microCi P 33 ⁇ -ATP
  • 15 ng CDK5/p25 complex inhibitor in a final volume of 30 ⁇ l buffer (TRIS HCl 10 mM pH 7.5, MgCl 2 10 mM, DTT 7.5 mM + 0.2 mg ml BSA) were added to each well of a 96 U bottom. After 30 min at r.t. incubation, reaction was stopped by 100 ⁇ l PBS + 32 mM EDTA + 0.1% Triton X-100 + 500 ⁇ M ATP, containing 1 mg SPA beads. Then a volume of 110 ⁇ l is transferred to Optiplate. After 20 min.
  • kinase reaction 0,4 ⁇ M mouse GST-Rb (769-921) (# sc-4112 from Santa Cruz) substrate, 10 ⁇ M ATP (0.5 ⁇ Ci P 33 ⁇ - ⁇ TP), 100 ng of baculovirus expressed GST- Cdk4/Cyclin DI, suitable concentrations of inhibitor in a final volume of 50 ⁇ l buffer (TRIS HCl 10 mM pH 7.5, MgCl 2 10 mM, 7.5 mM DTT+ 0.2mg/ml BSA) were added to each well of a 96 U bottom well plate. After 40 min at 37 °C incubation, reaction was stopped by 20 ⁇ l EDTA 120 mM.
  • Capture 60 ⁇ l were transferred from each well to Multiscreen plate, to allow substrate binding to phosphoceUulose filter. Plates were then washed 3 times with 150 ⁇ l/well PBS Ca + /Mg 'l+ free and filtered by Multiscreen filtration system. Detection: filters were allowed to dry at 37°C, then 100 ⁇ l/weU scintiUant were added and 33 P labeled Rb fragment was detected by radioactivity counting in the Top-Count instrument.
  • ICSO determination see above Inhibition assay of MAPK activity Kinase reaction: 10 ⁇ M in house biotinylated MBP (Sigma # M-1891) substrate, 15 ⁇ M ATP (0.15 microCi P 33 ⁇ -ATP), 30 ng GST-MAPK (Upstate Biothecnology # 14- 173), inhibitor in a final volume of 30 ⁇ l buffer (TRIS HCl 10 mM pH 7.5, MgCl 2 10 mM, DTT 7.5 mM + 0.2 mg/ml BSA) were added to each well of a 96 U bottom. After 30 min at r.t.
  • reaction was stopped by 100 ⁇ l PBS + 32 mM EDTA + 0.1% Triton X-100 + 500 ⁇ M ATP, containing 1 mg SPA beads. Then a volume of 110 ⁇ l is transferred to Optiplate.
  • kinase reaction 10 ⁇ M in house biotinylated MBP (Sigma # M-1891) substrate, 2 ⁇ M ATP (0.04 microCi P 3 ⁇ -ATP), 36 ng insect cell expressed GST-EGFR, inhibitor in a final volume of 30 ⁇ l buffer (Hepes 50 mM pH 7.5, MgCl 2 3 M, MnCl 2 3 mM, DTT 1 mM, NaV0 3 3 ⁇ M + 0.2 mg/ml BSA) were added to each well of a 96 U bottom. After 20 min at r.t.
  • Biotinylated peptide 4 repeats of LRRWSLG
  • 10 ⁇ M ATP 0.5 uCi P 33 ⁇ -ATP
  • 15 ng Aurora2, inhibitor in a final volume of 30 ⁇ l buffer (HEPES 50 mM pH 7.0, MgCl 2 10 mM, 1 mM DTT, 0.2 mg/ml BSA, 3 ⁇ M orthovanadate) were added to each well of a 96 U bottom well plate. After 30 minutes at room temperature incubation, reaction was stopped and biotinylated peptide captured by adding 100 ⁇ l of bead suspension.
  • the inhibition assay of Cdc7/dbf4 activity was performed according to the following protocol.
  • Biotin-MCM2 substrate is trans-phosphorylated by the Cdc7/Dbf4 complex in the presence of ATP traced with ⁇ - ⁇ TP.
  • the phosphorylated Biotin-MCM2 substrate is then captured by Streptavidin-coated SPA beads and the extent of phosphorylation evaluated by ⁇ counting.
  • the inhibition assay of Cdc7/dbf4 activity was performed in 96 wells plate according to the following protocol. To each well of the plate were added:
  • test compound (12 increasing concentrations in the nM to ⁇ M range to generate a dose-response curve) - 10 ⁇ l of a mixture of cold ATP (lO ⁇ M final concentration) and radioactive ATP (1/2500 molar ratio with cold ATP) was then used to start the reaction which was allowed to take place at 37°C.
  • Substrate, enzyme and ATP were diluted in 50 mM HEPES pH 7.9 containing 15 mM MgCl 2 , 2 mM DTT, 3 ⁇ M NaVG 3 , 2mM glycerophosphate and 0.2mg/ml BSA.
  • the solvent for test compounds also contained 10% DMSO.
  • the compounds of formula (I) ofthe invention resulted to possess a remarkable kinase inhibitory activity.
  • novel compounds of the invention are unexpectedly endowed with a cdk inhibitory activity significantly higher than that of the structurally closest prior art compounds of WO 02/12242 and are thus particularly advantageous, in therapy, against proliferative disorders associated with an altered ceU cycle dependent Idnase activity.
  • the compounds of formula (I) of the present invention suitable for administration to a mammal, e.g. to humans, can be administered by the usual routes and the dosage level depends upon the age, weight, conditions ofthe patient and the administration route.
  • a suitable dosage adopted for oral administration of a compound of formula (I) may range from about 10 to about 500 mgpro dose, from 1 to 5 times daily.
  • the compounds of the invention can be administered in a variety of dosage forms, e.g.
  • parenteraUy e.g. intramuscularly, or by intravenous and/or intrathecal and or intraspinal injection or infusion.
  • the compounds of the invention can be administered either as single agents or, alternatively, in combination with known anticancer treatments such as radiation therapy or chemotherapy regimen in combination with cytostatic or cytotoxic agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g.
  • COX-2 inhibitors COX-2 inhibitors
  • metallomatrixprotease inhibitors telomerase inhibitors
  • tyrosine kinase inhibitors anti-growth factor receptor agents, anti-HER agents, anti-EGFR agents, anti- angiogenesis agents, farnesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, cell cycle inhibitors, other cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors and the like, optionally within liposomal formulations thereof.
  • compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable excipient (which can be a carrier or a diluent).
  • a pharmaceutically acceptable excipient which can be a carrier or a diluent.
  • the pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.
  • the solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, sucrose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gum, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g.
  • diluents e.g. lactose, dextrose, saccharose, sucrose, cellulose, corn starch or potato starch
  • lubricants e.g. silica, talc, stearic, magnesium or calcium stearate, and/or polyethylene glycols
  • binding agents e.g. starches, arabic gum, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl
  • a starch alginic, alginates or sodium starch glycolate
  • effervescing mixtures dyestuffs
  • sweeteners wetting agents such as lecithin, polysorbates, laurylsulfates
  • wetting agents such as lecithin, polysorbates, laurylsulfates
  • non-toxic and pharmacologicaUy inactive substances used in pharmaceutical formulations.
  • Said pharmaceutical preparations may be manufectured according to known techniques, for example by means of mixing, granulating, tabletting, sugar- coating, or film-coating processes.
  • the liquid dispersions for oral administration may be, e.g., syrups, emulsions and suspensions.
  • the syrups may contain as carrier, for example, saccharose or saccharose with glycerin and/or mannitol and/or sorbitol.
  • the suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylceUulose, or polyvinyl alcohol.
  • the suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride.
  • the solutions for intravenous injections or infusions may contain as a carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions or they may contain as a carrier propylene glycol.
  • a carrier for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions or they may contain as a carrier propylene glycol.
  • the suppositories may contain together with the active compound a pharmaceutically acceptable carrier, e.g. cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty ester surfactant or lecithin.
  • Mobile phase A was ammonium acetate 5 mM buffer (pH 5.5 with acetic acid/acetonitrile 95:5), and Mobile phase B was H 2 0/acetonitrile (5:95).
  • CapiUary voltage was 2.5 KV; source temperature was 120°C; cone was 10 V.
  • Retention times (HPLC r.t.) are given in minutes at 220 nm or at 254 nm. Mass are given as m z ratio.
  • the foUowing compounds may be also obtained:
  • the reaction mixture was stirred at 100°C for 48 hours.
  • the solution was washed with water and the organic product was extracted with ethyl acetate.
  • the organic layers were combined, washed with brine, dried over sodium sulfate, filtered and dried under vacuum.
  • the crude material was purified by flash chromatography on silica gel, using cyclohexane:ethyl acetate as eluent to yield the title compound.
  • Example 18 Preparation of 3-amino-5-tert-bntyloxycarbonyH-ethoxycarbonyl-pyrazolo [4,3- c] 4,5,6,7-tetrahydropyridine.
  • 3-amino-5-tert-butyloxycarbonyl-pyrazolo[4,3-c]4,5,6,7-tetrahydro pyridine 94.1 g, 0.395 moles
  • N,N-diisopropylethylamine (135 ml, 0.79 moles) in tetrahydrofuran (1700 ml)
  • ethylchlorformate 98% assay, 37.6 ml, 0.395 moles) in tetrahydrofuran (300 ml) was added dropwise at 0°C in 75 minutes.
  • Trityl chloride resin (1 g, loading 1.27 mmol/g) was sweUed with 3 ml of dichloromethane.
  • Example 24 Preparation of 3-(4-tert-butyl-benzamido)-l-poIysryrenetriryl-5-[(2- methanesuIfonyl)pyrimidin-4-yI]-pyrazolo[4,3-c]4,5,6,7-tetrahydropyridine
  • a solution of m-chloroperbenzoic acid and NaOH (1/1) was added dropwise to a solution of 3-(4-tert-bu1yl-ber_zamido)-l-polys1yrenetri1yl-5-[(2-methylt__uo)pyriinidin-4- yl]-pyrazolo[4,3-c]4,5,6,7-tetrahydropyridine in dioxane.
  • the foUowing compounds may be also obtained: 3-(4-tert-butyl-benzamido)-l-polystyrenetrityI-5-[(2-benzylamino)pyrimidin-4-yl]- pyrazolo [4,3-c] 4,5,6,7-tetrahydropyridine;

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compounds which are pyrrolo-pyrazole derivatives and pharmaceutically acceptable salts thereof, together with the process for their preparation and pharmaceutical compositions thereof are disclosed; these compounds or compositions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.

Description

BICYCLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AHD PHARB ACEUTICAL COMPOSITIONS COMPRISING THEM The present invention relates to bicyclo-pyrazole derivatives active as kinase inhibitors and, more in particular, it relates to pyrrolo-pyrazole derivatives, to a process for their preparation, to pharmaceutical compositions comprising them and to their use as therapeutic agents, particularly in the treatment of diseases linked to disregulated protein kinases. The disregulation of protein kinases (PK) activity is the hallmark of numerous diseases. A large share of the oncogenes and proto-oncogenes involved in human cancers code for PKs. The enhanced activities of PKs are also implicated in many non-malignant diseases, such as benign prostate hyperplasia, femilial adenomatosis, polyposis, neuro- fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis. PKs are also implicated in inflammatory conditions and in the multiplication of viruses and parasites. PKs may also play a major role in the pathogenesis and development of neurodegenerative disorders. For a general reference to PKs malfunctioning or disregulation see, for instance, Current Opinion in Chemical Biology 1999, 3, 459 - 465.
It is an object of the invention to provide compounds which are useful in therapy as agents against a host of diseases caused by and or associated to a disregulated protein kinase activity. It is another object to provide compounds which are endowed with multiple protein kinase inhibiting activity.
The present inventors have now discovered that some pyrrolo-pyrazole derivatives are endowed with multiple protein kinase inhibiting activity and are thus useful in therapy in the treatment of diseases associated with disregulated protein kinases. More specifically, the compounds of this invention are useful in the treatment of a variety of cancers including, but not limited to: carcinoma such as bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematσpoietic tumors of lymphoid lineage, including leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgldn's lymphoma, non-Hodgldn's lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma and schwannomas; other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid foUicular cancer and Kaposi's sarcoma.
Due to the key role of PKs in the regulation of cellular proliferation, these pyrrolo- pyrazole derivatives are also useful in the treatment of a variety of cell proliferative disorders such as, for instance, benign prostate hyperplasia, femilial adenomatosis, polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis.
The compounds ofthe invention can be useful in the treatment of Alzheimer's disease, as suggested by the feet that cdk5 is involved in the phosphorylation of tau protein (J. Biochem., 117, 741-749, 1995).
The compounds of this invention, as modulators of apoptosis, may also be useful in the treatment of cancer, viral infections, prevention of ADDS development in HIV-infected individuals, autoimmune diseases and neurodegenerative disorders. The compounds of this invention may be useful in inhibiting tumor angiogenesis and metastasis, as well as in the treatment of organ transplant rejection and host versus graft disease.
The compounds of the invention may also act as inhibitor of other protein kinases, e.g., protein kinase C in different isoforms, Met, PAK-4, PΛK-5, ZC-1, STLK-2, DDR-2, Aurora 1, Aurora 2, Bub-1, PLK, Chkl, Chk2, HER2, rafl, MEK1, MAPK, EGF-R, PDGF-R, FGF-R, IGF-R, PI3K, weel kinase, Src, Λbl, Akt, MAPK, ILK, MK-2, IKK-2, Cdc7, Nek, and thus be effective in the treatment of diseases associated with other protein Idnases.
The compounds of the invention are also useful in the treatment and prevention of radiotherapy-induced or chemotherapy-induced alopecia. Several heterocyclic compounds are known in the art as protein Idnase inhibitors.
Among them are heterocyclic urea derivatives disclosed in WO 99/32455 as RΛF Idnase inhibitors, and aminopyrazole derivatives disclosed in WO 97/40019 as selective protein tyrosine kinase inhibitors. Amino-pyrimidine compounds are disclosed as p38 kinase inhibitors in WO 03/02544. In addition, 2-carboxamido- and 2-ureido-pyrazole compounds have been disclosed as protein kinase inhibitors in the international patent applications WO 01/12189, WO
01/12188, WO 02/48114 and WO 02/70515, all in the name ofthe applicant itself.
Fused bicyclic compounds comprising pyrazole moieties and possessing kinase inhibitory activity have been also disclosed in WO 00/69846 and WO 02/12242, both in the name ofthe applicant itself.
The compounds object of the present invention fall within the scope of the general formula of the aforementioned WO 02/12242, herewith incorporated by reference, but are not specifically exemplified therein.
Accordingly, the present invention provides a method for treating diseases caused by and/or associated with an altered protein kinase activity, by administering to a mammal in need thereof an effective amount of a pyrazole represented by formula (I)
Figure imgf000004_0001
wherein
R is a hydrogen atom or a group selected from -COR', -COOR', -CONHR', -C(=NH)NHR', -S02R' or -S02NR'R"; Ri is an optionally substituted 5 or 6 membered heterocyclic group with from 1 to 3 heteroatoms or heteroatomic groups selected from N, NR', O or S, optionally benzocondensed;
R2 is hydrogen or it is selected from the group consisting of R', -COR.', -COOR', -CONR'R" or -S(0)qR';
R and 4 are both hydrogen atoms or methyl groups or, together with the carbon atom to which they are attached, form a cyclopropyl group;
R' and R" are, the same or different and independently in each ofthe above occasions, a hydrogen atom or an optionally substituted group selected from straight or branched Cj-Cβ alkyl, C3-C6 cycloalkyl, aryl, aryl Ci-Cβ alkyl, heterocyclyl or heterocyclyl Ci-Cβ alkyl; m and n are 0 or 1, provided that they are not both 1; q is 0 or an integer from 1 to 2; and the pharmaceutically acceptable salts thereof. In a preferred embodiment ofthe method described above, the disease caused by and/or associated with an altered protein kinase activity is selected from the group consisting of cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.
Specific types of cancer that may be treated include carcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system, melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid foUicular cancer and Kaposi's sarcoma.
In another preferred embodiment of the method described above, the cell proliferative disorder is selected from the group consisting of benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post- surgical stenosis and restenosis.
In addition, the method object ofthe present invention, also provides tumor angiogenesis and metastasis inhibition.
The present invention ftirther provides a pyrazole represented by formula (I)
Figure imgf000006_0001
wherein
R is a hydrogen atom or a group selected from -COR', -COOR', -CONHR',
-C(=NH)NHR', -S02R' or -S02NR'R"; Ri is an optionally substituted 5 or 6 membered heterocyclic group with from 1 to 3 heteroatoms or heteroatomic groups selected from N, NR', O or S, optionally benzocondensed;
R2 is hydrogen or it is selected from the group consisting of R', -COR', -COOR',
-CONR'R" or -S(0)qR'; R3 and R are both hydrogen atoms or methyl groups or, together with the carbon atom to which they are attached, form a cyclopropyl group;
R' and R" are, the same or different and independently in each ofthe above occasions, a hydrogen atom or an optionally substituted group selected from straight or branched
Cι-C6 alkyl, C3-C6 cycloalkyl, aryl, aryl Cι-C6 alkyl, heterocyclyl or heterocyclyl Cι-C6 alkyl; m and n are 0 or 1, provided that they are not both 1; q is 0 or an integer from 1 to 2; and the pharmaceutically acceptable salts thereof.
The compounds of formula (I), object of the present invention, may have asymmetric carbon atoms and may therefore exist either as racemic admixtures or as individual optical isomers.
Accordingly, all the possible isomers and their admixtures and of both the metabolites and the pharmaceutically acceptable bio-precursors (otherwise referred to as pro-drugs) of the compounds of formula (I), as well as any Iherapeutic method of treatment comprising them, are also within the scope ofthe present invention. In the present description, unless otherwise indicated, with the term straight or branched Ci-Cβ alkyl we intend a group such as, for instance, methyl, ethyl, n-propyl, isopropyl, n- butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl and the like. With the term C3-C6 cycloalkyl we intend a group such as, for instance, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
With the term aryl we intend a mono- or bi- either carbccyclic as well as heterocyclic group with from 1 to 2 ring moieties, either fused or linked to each other by single bonds, wherein at least one ofthe carbocyclic or heterocyclic rings is aromatic. Non limiting examples of aryl groups are, for instance, phenyl, indanyl, biphenyl, α- or β-naphthyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,3,5-triazinyl, indolyl, imidazolyl, inmidazopyridyl, 1,2-methylenedioxyphenyl, thiazolyl, isothiazolyl, pyrrolyl, pyrrolyl-phenyl, furyl, phenyl-furyl, benzotetrahydrofuranyl, oxazolyl, isoxazolyl, pyrazolyl, chromenyl, thienyl, benzothienyl, isoindolinyl, benzoimidazolyl, benzoxazolyl, benzothiazolyl, isoindolinyl-phenyl, quinolinyl, isoquinolinyl, quinoxalinyl, pyrazinyl, benzofurazanyl, 1,2,3-triazolyl, 1 -phenyl- 1,2,3-triazolyl, and the like.
With the term 5 or 6 membered heterocycle, hence encompassing aromatic heterocyclic groups also referred to as aryl groups, we further intend a saturated or partially unsaturated 5 or 6 membered carbocycle wherein one or more carbon atoms are replaced by 1 to 3 heteroatoms or heteroatomic groups such as N, NR', O or S, wherein R' is as defined in the general formula.
Additional examples of 5 or 6 membered heterocyclic groups optionally benzocondensed or further substituted, besides those previously referred to as aryl groups, are 1,3- dioxolane, pyran, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, pyrazoline, piperidine, piperazine, morpholine, tetrahydrofuran, and the like. According to the above meanings provided to R1; R' and R", any ofthe said groups may be further optionally substituted in any of the free positions by one or more groups, for instance 1 to 6 groups, selected from: halogen, nitro, oxo groups (=0), carboxy, cyano, alkyl, polyfluorinated alkyl, hydroxyalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, amino groups and derivatives thereof such as, for instance, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkylamino, dialkylamino, cycloalkylamino, arylamino, diaiylamino, arylalkylamino, ureido, alkylureido or arylureido; carbonylamino groups and derivatives thereof such as, for instance, formylamino, allsylcarbonylamino, alkenylcarbonylamino, arylcarbonylamino, alkoxycarbonylamino; hydroxy groups and derivatives thereof such as, for instance, alkoxy, aryloxy, arylalkyloxy, heterocyclyloxy, alkylcarbonyloxy, arylcarbonyloxy, cycloalkenyloxy or all ylideneaminooxy; carbonyl groups and derivatives thereof such as, for instance, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, cycloalkyloxycarbonyl, aminoca bonyl, alkylaminocarbonyl, dialkylaminocarbonyl; sulfurated derivatives such as, for instance, alkylthio, arylthio, alkylsulfonyl, arylsulfonyl, alkylsulfinyl, arylsulfinyl, arylsulfonyloxy, aminosulfonyl, alkylaminosulfonyl or dialkylaminosulfonyl. In their turn, whenever appropriate, each ofthe above groups may be further substituted by one or more ofthe aforementioned groups.
Among these latter groups and unless otherwise specified in the present description, with the term halogen atom we intend a fluorine, chlorine, bromine or iodine atom. With the term polyfluorinated alkyl we intend a straight or branched Ci-Cβ alkyl group as above defined, wherein more than one hydrogen atom is replaced by fluorine atoms. Example of polyfluorinated alkyl groups are, for instance, trifiuoromethyl, 2,2,2- trifluoroethyl, 1,2-difluoroethyl, l,l,l,3,3,3-hexafluoropropyl-2-yl and the like. With the term alkenyl or alkynyl we intend a straight or branched unsaturated hydrocarbon chain having a double or triple bond, with from 2 to 6 carbon atoms such as, for instance, vinyl, ethynyl, 1 -propenyl, allyl, 1- or 2-propynyl, 1-, 2- or 3 -butenyl, 1-, 2- or 3-butynyl, pentenyl, pentynyl, hexenyl, hexynyl and the like. From all of the above, it is clear to the skilled person that any group which name has been identified as a composite name such as, for instance, cycloalkylalkyl, arylalkyl, heterocyclylalkyl, alkoxy, alkylthio, aryloxy, arylalkoxy, heterocyclyloxy, heterocyclylalkoxy, alkylcarbonyloxy and the like, have to be intended as conventionally construed from the parts to which they derive.
As an example, the term heterocyclyl-alkyl stands for an alkyl group being further substituted by a heterocyclyl group, wherein alkyl and heterocyclyl are as above defined. Pharmaceutically acceptable salts of the compounds of formula (I) are the acid addition salts with inorganic or organic acids, e.g. nitric, hydrochloric, hydrobromic, sulfuric, perchloric, phosphoric, acetic, trifluoroacetic, propionic, glycolic, lactic, oxalic, malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic, methanesulfonic, isethionic and salicylic acid, as well as the salts with inorganic or organic bases, e.g. alkali or alkaline-earth metals, especially sodium, potassium, calcium or magnesium hydroxides, carbonates or bicarbonates, acyclic or cyclic amines, preferably methylamine, ethylamine, diethylamine, triethylamine or piperidine.
When referring to the compounds of formula (T) ofthe invention, it is clear to the sldlled person that the group R2 may be linked to any one ofthe adjacent nitrogen atoms ofthe pyrazole ring, so as to give rise to two different tautomeric forms, as reported below, being both comprised within the scope ofthe invention:
Figure imgf000009_0001
In addition, it also clear that depending upon the nature of the R3 and R4 groups and of the meanings of m and n, the following compounds ofthe invention are thus identified:
Figure imgf000010_0001
A first class of preferred compounds ofthe invention is represented by the derivatives of formula (I) wherein R2 is hydrogen or a group -COOR', wherein R' is a straight or branched Cι-C6 alkyl group.
Even more preferred, within this class, are the compounds of formula (I) wherein R2 is hydrogen or a group -COOR' wherein R' is ethyl.
Another class of preferred compounds ofthe invention is represented by the derivatives of formula (T) wherein Ri is an optionally substituted heterocycle selected from pyrimidine, thiazole or benzothiazole.
Even more preferred, within this class, are the compounds of formula (I) wherein Ri is a pyrimidine ring optionally substituted by one or more groups selected from halogen, heterocycles, alkylheterocycles, hydroxyalkylheterocycles, alkoxy, heterocyclyloxy, alkylheterocyclyloxy, alkylthio, alkylsulfonyl, alkylamino, cycloaUcylamino, aiylamino and arylallcylamino, wherein heterocyclyl, allsyl, cycloallcyl and aryl are as above defined. Still more preferred, in any one of the above classes, are the derivatives of formula (I) wherein m is 0 or 1 and n is 0.
Specific examples of compounds of formula (I), optionally in the form of pharmaceutically acceptable salts, are reported in the experimental section.
As set forth above, it is a further object of the present invention a process for preparing the pyrazole compounds of formula (I).
Therefore, the compounds of formula (I) and the pharmaceutically acceptable salts thereof may be prepared by a process comprising: a) reacting under acidic or basic conditions a compound of formula (II)
Figure imgf000011_0001
wherein R3, , m and n are as defined in formula (I), Q represents a suitable nitrogen protecting group and Q' represents R2 or a suitable nitrogen protecting group; so as to obtain a compound of formula (UT)
Figure imgf000011_0002
b) reacting the compound of formula (III) with a derivative of formula (IV)
Figure imgf000011_0003
wherein Ri is as defined in formula (I) and X represents a halogen atom or a suitable leaving group, so as to obtain a compound of formula (V)
Figure imgf000012_0001
c) reacting the compound of formula (V) with a suitable derivative of formula (VI),
Cvπ), (vιπ), (ix), pc) or (xi)
R'COX (VI); R'OCOX (VII); R"NCO (VIII); H2N-C(=NH)NH2 (IX); XS02R' (X); XS02 R'R" (XI) wherein R' and R" are as defined in formula (T) and X is a halogen atom or a suitable leaving group, so as to obtain the corresponding compound of formula (I) below
Figure imgf000012_0002
and, optionally, d) converting it into another compound of formula (I) or into a pharmaceutically acceptable salt thereof.
According to step (a) of the process, the compound of formula (II) is treated under acidic or basic conditions, in the presence of a suitable solvent, for instance dichloromethane or 1,4-dioxane, at room temperature, so as to get the compound of formula (III).
The choice of using basic or acidic conditions is driven by the nature of the Q and Q' groups, as this reaction enables selective deprotection ofthe Q group at the non-pyrazole nitrogen atom without affecting the Q' group at the pyrazole nitrogen atom. Preferably, within the compound of formula (II), Q represents the group tert- butoxycarbonyl (boc) whereas Q' is a hydrogen atom or a group R2 of formula -COOR' wherein R' is lower alkyl, for instance ethyl. In this case, the compound of formula (II) may be treated under acidic conditions, for instance in the presence of trifluoroacetic or hydrochloric acid, so as get cleavage ofthe Q group to the corresponding compound of formula (UI).
Clearly, by working under acidic conditions, the compound of formula (III) will be in the form of an addition salt, e.g. as a trifluoroacetate or chloridrate salt
According to step (b) ofthe process, the compound of formula (IU) is then reacted with a suitable derivative of formula (TV) so as to get the compound of formula (V). The reaction is carried out under basic conditions, for instance in the presence of a suitable alkali carbonate, e.g. potassium carbonate, or of a tertiary base, e.g. diisopropylethylamine.
The reaction is carried out in a suitable solvent such as dimethylsulfoxide (DMSO), dimethylformamide, acetonitrile, isopropanol or n-butanol, at a temperature ranging from room temperature to refluxing temperature. Preferably, within the compound of formula (TV), X represents a chlorine atom or a suitable leaving group such as an alkylsulfonyl or arylsulfonyl group.
According to step (c) of the process, the compound of formula (V) is then reacted with any one of the alternative compounds of formula from (VI) to (XI), so as to get the corresponding compound of formula (I) being properly fύnctionalized at the amino position. From the above, it is clear to the skilled person that by reacting the compound of formula (V): with a derivative of formula (VI), compounds having R as a -COR' group may be obtained; with a derivative of formula (VD), compounds having R as a -COOR' group may be obtained; with a derivative of formula (VIII), compounds having R as a - CONHR' group may be obtained; with a derivative of formula (IX), compounds having R as a
-C(=NH)NH2 group may be obtained; with a derivative of formula (X), compounds having R as a -S02R' group may be obtained and; finally, with a derivative of formula (XI), compounds having R as a -S02NR'R" group may be obtained. Any of the above reactions and operative conditions thereof are widely known in the art as they allow to obtain a variety of carboxamido, carbamato, ureido, amidino, sulfonamido or sulfonylureido derivatives. The compounds of formula (I) thus obtained may be then converted, according to step (d) ofthe process, in a variety of other compounds of formula (I) ofthe invention, and/or into pharmaceutically acceptable salts thereof, by working according to conventional methods. As an example, the compounds of formula (I) wherein Q' stands for a nitrogen protecting group may be easily deprotected according to known methods, for instance under acidic or basic conditions as the case may be, so as to obtain the corresponding compounds wherein R2 stands for hydrogen; their subsequent functionaUzation at the pyrazole nitrogen atom may then allow to insert any desired R2 group. Likewise, as an additional example of conversion according to step (d), the amidino compounds of formula (I) wherein R stands for -C(=NH)NH2 may be easily converted into a variety of derivatives wherein R is a -C(=NH)MHR' group, by means of known methods, for instance in the presence of a suitable amino derivative RTSTH^ wherein R' is as above defined From all ofthe above, it is also clear that any optional substituent that is part of Ri, R' or R" and that is further susceptible of being converted into another group may also lead to a variety of derivatives.
As a non limiting example, carboxy groups may be converted into a variety of derivatives including esters and amides; carboxamides may undergo reduction to amino derivatives; alkylthio groups may be oxidized to alkylsulfinyl or alkylsulfonyl groups or even replaced by amino or alkoxy groups and derivatives thereof; chlorine atoms may be replaced by amino or alkoxy groups and derivatives thereof; nitro groups can be reduced to amines; amines may be further acylated to carboxamides, and the like. For a general reference to any one ofthe above reactions, herewith conveniently grouped into step (d) of the process, and to the operative conditions thereof (for instance including the use of microwave and of given apparatus, according to methods known in the art), see the experimental section.
When preparing the compounds of formula (I) according to any variant of the process, which are all to be intended as within the scope of the present invention, optional functional groups within both the starting materials, the reagents or the intermediates thereof and which could give rise to unwanted side reactions, need to be properly protected according to conventional techniques.
Likewise, the conversion of these latter into the free deprotected compounds may be carried out according to known procedures.
By analogy, pharmaceutically acceptable salts of the compounds of formula (I) or, alternatively, their free compounds from the salts thereof, my be all obtained according to conventional methods.
From all ofthe above, it is also clear to the person skilled in the art that if a compound of formula (I), prepared according to the above process, is obtained as an admixture of isomers, their separation into the single isomers of formula (I), carried out according to conventional techniques, is still within the scope ofthe present invention.
The compounds of formula (I) may be also prepared according to an alternative synthetic approach represented below, still to be intended as comprised within the scope of the invention:
Figure imgf000015_0001
From the above, it is clear to the skilled person that the operative conditions being employed in this latter process are substantially analogous to those of the previous one, with the exception that some steps are carried out according to a different order. In step (1), in fact, the compound of formula (II) is first reacted so as to get the desired amino derivative (-NHR) as per previous step (c); in step (2), the intermediate thus obtained is deprotected at the non-pyrazole nitrogen atom and subsequently reacted with a compound of formula (IV), as per previous step (b); finally, in step (3), the obtained compound is further converted into the derivative of formula (I) as per previous step (d). For a general reference to the above process and operative conditions thereof, see the experimental section.
Very advantageously, the compounds of formula (I) of the invention may be also prepared under solid-phase-synthesis (SPS) conditions, which are typicaUy adopted when preparing libraries of compounds according to combinatorial chemistry techniques. Therefore, it is a further object of the invention, a process for preparing the compounds of formula (I) of the invention which comprises: e) hydrolyzing under acidic or basic conditions the compound of formula (I) being obtained in previous step (c) wherein R, Rj, R3, R4, m and n have the above reported meanings and Q' is a suitable pyrazole nitrogen protecting group
Figure imgf000016_0001
and reacting the thus obtained compound bearing a hydrogen atom in place of Q' in the presence of a suitable polymeric resin (P), so as to obtain the resin supported compound of formula (XH)
Figure imgf000016_0002
f) optionally converting the compound of formula (XH) into another compound of formula (XII), and g) cleaving the polymeric resin so as to obtain the desired compound of formula (I) and, whenever desired, converting it into a pharmaceutically acceptable salt thereof. According to step (e) ofthe process, the compound of formula (I) being obtained in step
(c) is first deprotected at the pyrazole nitrogen atoms according to conventional means, for instance under acidic or basic hydrolysis conditions.
The obtained derivative is then conveniently anchored to an inert polymeric support (P) such as, for instance, 2-chloro-trityl chloride resin, trityl chloride resin, p-nitrophenyl carbonate Wang resin, or an isocyanate polystyrenic resin, which are all conventionally known in this field.
Typically, for instance when Q' is a ca boxyester group -COOR', the cleavage of the Q' group may occur under basic conditions and in the presence ofthe polymeric resin, so as to allow loading ofthe pyrazole intermediate onto the solid phase.
The reaction may be carried out in the presence of a slight excess of a suitable base, for instance an amine such as diisopropylethylamine (DIPEA), triethylamine (TEA), 1,8- diazabiciclo[5.4.0]undec-7-ene (DBU) or 2-tert-butyUm__no-2-die1hylamino-l,3- dimethylρerhydro-l,3,2-diaza-ρhosphorine, in a suitable solvent such as, for instance, dichloromethane, chloroform, methanol, tetrahydrofuran, dimethylformamide, dimethylacetamide, and the like.
The reaction may be performed by adding to a suspension o the resin, the base and the compound of formula (I) to be supported, under stirring and at a temperature ranging from room temperature to about 55°C for a suitable time, for instance up to 96 hours. The polymer supported compound of formula (XII) thus obtained may be reacted, in step (f), so as to give rise to a variety of derivatives, substantially as set forth above in step
(d) of the process.
Finally, in step (g), the compound of formula (XII) is cleaved from the resin to which it is supported; resin cleavage may be carried out, for instance, in the presence of trifluoroacetic acid so as to yield the desired compound of formula (I). The compound of formula (XII) is thus suspended in a solution of 5-95% of trifluoroacetic acid in dichloromethane, and the mixture is stirred at room temperature for a suitable time, for instance from a few minutes to about 3 hours.
Alternatively, resin cleavage may be also carried out under basic conditions, for instance in the presence of aqueous potassium or sodium hydroxide and in the presence of a suitable co-solvent such as methanol, ethanol, dimethylformamide, 1,4-dioxane or acetonitrile, so as to yield the desired compound of formula (1). The compound of formula (XII) is thus suspended in a solution of 35% of sodium or potassium hydroxide, for instance in methanol, by worldng under mild operative conditions at temperatures ranging from about 5°C to about 60°C and for a time varying from about 2 hours to about 7 days.
The compound of formula (II), as a starting material of each one ofthe above processes, comprehensive of any variant thereof, is known or can be easUy obtained according to known methods.
In particular, the compound of formula (II) wherein Q is tert-butoxycarbonyl (boc) and Q' is ethoxycarbonyl (-COOEt), as per the formula below
Figure imgf000018_0001
is known and may be prepared as described in the aforementioned international patent application WO 02/12242. Likewise, any other derivative of formula (H) may be also prepared, by analogy, as described in WO 02/12242. In addition, the compounds of formula (TV) and of formula from (VI) to (XI), the polymeric resin as well as any other reactant ofthe processes ofthe invention, is known or can be prepared according to known methods.
As formerly indicated, the compounds of formula (I) may be conveniently prepared according to paraUel synthesis or combinatorial chemistry techniques widely known in the art, by accomplishing the aforementioned reactions between the several intermediates in a serial manner and by working under SPS (Solid Phase Synthesis) or Solution Phase
Synthesis conditions.
Accordingly, it is a ftirther object of the present invention a library of two or more pyrazole derivatives represented by formula (I)
Figure imgf000019_0001
wherein
R is a hydrogen atom or a group selected from -COR', -COOR', -CO HR',
-C(= H)NHR', -S02R' or -S02NR'R"; Ri is an optionally substituted 5 or 6 membered heterocyclic group with from 1 to 3 heteroatoms or heteroatomic groups selected from N, NR', O or S, optionally benzocondensed;
R2 is hydrogen or it is selected from the group consisting of R', -COR', -COOR',
-CONR'R" or -S(0)qR'; R3 and R are both hydrogen atoms or methyl groups or, together with the carbon atom to which they are attached, form a cyclopropyl group;
R' and R" are, the same or different and independently in each ofthe above occasions, a hydrogen atom or an optionally substituted group selected from straight or branched
Ci-Cβ alkyl, C3-C6 cycloalkyl, aryl, aryl C]-C6 alkyl, heterocyclyl or heterocyclyl Cι-C6 alkyl; m and n are 0 or 1, provided that they are not both 1 ; q is 0 or an integer from 1 to 2; and the pharmaceutically acceptable salts thereof.
From all of the above, it is clear to the skilled person that once a library of pyrazole derivatives is thus prepared, for instance consisting of several hundreds of compounds of formula (I), the said library can be very advantageously used for screening towards given kinases, as formerly reported.
See, for a general reference to libraries of compounds and uses thereof as tools for screening biological activities, J. Med. Chem. 1999, 42, 2373-2382; and Bioorg. Med. Chem. Lett. 10 (2000), 223 -226.
PHARMACOLOGY The compounds of formula (I) are active as protein Idnase inhibitors and are therefore useful, for instance, to restrict the unregulated proliferation of tumor cells. In therapy, they may be used in the treatment of various tumors, such as those formerly reported, as well as in the treatment of other cell proliferative disorders such as psoriasis, vascular smooth ceU proliferation associated with atherosclerosis and post-surgical stenosis and restenosis and in the treatment of Alzheimer's disease. The inhibiting activity of putative Cdk/Cyclin inhibitors and the potency of selected compounds is determined through a method of assay based on the use of the SPA technology (Amersham Pharmacia Biotech). The assay consists of the transfer of radioactivity labelled phosphate moiety by the kinase to a biotinylated substrate. The resulting 33P-labeUed biotinylated product is aUowed to bind to streptavidin-coated SPA beads (biotin capacity 130 pmol/mg), and light emitted is measured in a scintillation counter. Inhibition assay of Cdk2/Cvclin A activity Kinase reaction: 4 μM in house biotinylated histone HI (Sigma # H-5505) substrate, 10 μM ATP (0.1 microCi P33γ-ATP), 4.2 ng Cdk2/Cyclin A complex, inhibitor in a final volume of 30 μl buffer (TRIS HC1 10 mM pH 7.5, MgCl2 10 mM, DTT 7.5 mM + 0.2 mg ml BSA) were added to each weU of a 96 U bottom. After 30 min at r.t. incubation, reaction was stopped by 100 μl PBS + 32 mM EDTA + 0.1% Triton X-100 + 500 μM ATP, containing 1 mg SPA beads. Then a volume of 110 μl is transferred to Optiplate. After 20 min. incubation for substrate capture, lOpμl 5M CsCl were added to allow statification of beads to the top of the plate and let stand 4 hours before radioactivity counting in the Top-Count instrument IC50 determination: inhibitors were tested at different concentrations ranging from 0.0015 to 10 μM. Experimental date were analyzed by the computer program GraphPad Prizm using the four parameter logistic equation: y = bottom+(top-bottom)/(l+10Λ((logIC50-x)*slope)) where x is the logarithm of the inhibitor concentration, y is the response; y starts at bottom and goes to top with a sigmoid shape. ICi calculation: Experimental method: Reaction was carried out in buffer (10 mM Tris, pH 7.5, 10 mM MgCl2, 0.2 mg/ml BSA, 7.5 mM DTT) containing 3.7 nM enzyme, histone and ATP (constant ratio of cold/labeled ATP 1/3000). Reaction was stopped with EDTA and the substrate captured on phosphomembrane (Multiscreen 96 well plates from Millipore). After extensive washing, the multiscreen plates are read on a top counter. Control (time zero) for each ATP and histone concentrations was measured.
Experimental design: Reaction velocities are measured at different four ATP, substrate (histone) and inhibitor concentrations. An 80-point concentration matrix was designed around the respective ATP and substrate Em values, and the inhibitor IC50 values (0.3, 1, 3, 9 fold the Km or IC50 values). A preliminary time course experiment in the absence of inhibitor and at the different ATP and substrate concentrations allow the selection of a single endpoint time (10 min) in the linear range ofthe reaction for the Ki determination experiment. Kinetic parameter estimates: Kinetic parameters were estimated by simultaneous nonlinear least-square regression using [Eq.l] (competitive inhibitor respect to ATP, random mechanism) using the complete data set (80 points):
v = — — [Eq.l]
Ki β where A=[ATP], B=[Substrate], I=[inhibitor], Vm= maximum velocity, Ka, Kb, Ki the dissociation constants of ATP, substrate and inhibitor respectively, α and β the cooperativity factor between substrate and ATP binding and substrate and inhibitor binding respectively.
In addition the selected compounds are characterized on a panel of ser/threo kinases strictly related to cell cycle (Cdk2/Cyclin E, Cdkl/cyclin BI, Cdk5/p25, Cdk4/Cyclin DI), and also for specificity on MAPK, PKA, EGFR, IGF1-R, Aurora-2 and Akt.
Inhibition assay of Cdk2/Cvclin E activity
Kinase reaction: 10 μlNtf in house biotinylated histone HI (Sigma # H5505) substrate,
30 μ ATP (0.3 micrfii P33γ-ATP), 4 ng GST-Cdk2/Cyclin E complex, inhibitor in a final volume of 30 μl buffer (TRIS HC1 10 mM pH 7.5, MgCl2 10 mM, DTT 7.5 mM + 0.2 mg/ml BSA) were added to each well of a 96 U bottom. After 60 min at r.t. incubation, reaction was stopped by 100 μl PBS + 32 mM EDTA + 0.1% Triton X-100 + 500 μM ATP, containing 1 mg SPA beads. Then a volume of 110 μl is transferred to Optiplate. After 20 min. incubation for substrate capture, 100 μl 5M CsCl were added to aUow statification of beads to the top of the plate and let stand 4 hours before radioactivity counting in the Top-Count instrument IC50 determination: see above Inhibition assay of Cdkl/Cvclin BI activity Kinase reaction: 4 μM in house biotinylated histone HI (Sigma # H-5505) substrate, 20 μMAT P (0.2 microCi P33γ-ATP), 3 ng Cdkl/Cyclin B complex, inhibitor in a final volume of 30 μl buffer (TRIS HCl 10 mM pH 7.5, MgCl2 10 mM, DTT 7.5 mM + 0.2 mg ml BSA) were added to each well of a 96 U bottom. After 20 min at r.t. incubation, reaction was stopped by 100 μl PBS + 32 mM EDTA + 0.1% Triton X-100 + 500 μM ATP, containing 1 mg SPA beads. Then a volume of 110 μl is transferred to Optiplate. After 20 min. incubation for substrate capture, 100μl 5M CsCl were added to allow statification of beads to the top ofthe Optiplate and let stand 4 hours before radioactivity counting in the Top-Count instrument. IC50 determination: see above Inhibition assay of Cdk5/p25 activity
The inhibition assay of Cdk5/p25 activity was performed according to the foUowing protocol.
Kinase reaction: 10 μM biotinylated histone HI (Sigma # H-5505) substrate, 30 μM
ATP (0.3 microCi P33γ-ATP), 15 ng CDK5/p25 complex, inhibitor in a final volume of 30 μl buffer (TRIS HCl 10 mM pH 7.5, MgCl2 10 mM, DTT 7.5 mM + 0.2 mg ml BSA) were added to each well of a 96 U bottom. After 30 min at r.t. incubation, reaction was stopped by 100 μl PBS + 32 mM EDTA + 0.1% Triton X-100 + 500 μM ATP, containing 1 mg SPA beads. Then a volume of 110 μl is transferred to Optiplate. After 20 min. incubation for substrate capture, lOOμl 5M CsCl were added to aUow statification of beads to the top of the plate and let stand 4 hours before radioactivity counting in the Top-Count instrument. ICSO determination: see above Inhibition assay of Cdk4/Cyclin DI activity
Kinase reaction: 0,4 μM mouse GST-Rb (769-921) (# sc-4112 from Santa Cruz) substrate, 10 μM ATP (0.5 μCi P33γ-ΛTP), 100 ng of baculovirus expressed GST- Cdk4/Cyclin DI, suitable concentrations of inhibitor in a final volume of 50 μl buffer (TRIS HCl 10 mM pH 7.5, MgCl2 10 mM, 7.5 mM DTT+ 0.2mg/ml BSA) were added to each well of a 96 U bottom well plate. After 40 min at 37 °C incubation, reaction was stopped by 20 μl EDTA 120 mM.
Capture: 60 μl were transferred from each well to Multiscreen plate, to allow substrate binding to phosphoceUulose filter. Plates were then washed 3 times with 150 μl/well PBS Ca +/Mg'l+ free and filtered by Multiscreen filtration system. Detection: filters were allowed to dry at 37°C, then 100 μl/weU scintiUant were added and 33P labeled Rb fragment was detected by radioactivity counting in the Top-Count instrument.
ICSO determination: see above Inhibition assay of MAPK activity Kinase reaction: 10 μM in house biotinylated MBP (Sigma # M-1891) substrate, 15 μM ATP (0.15 microCi P33γ-ATP), 30 ng GST-MAPK (Upstate Biothecnology # 14- 173), inhibitor in a final volume of 30 μl buffer (TRIS HCl 10 mM pH 7.5, MgCl2 10 mM, DTT 7.5 mM + 0.2 mg/ml BSA) were added to each well of a 96 U bottom. After 30 min at r.t. incubation, reaction was stopped by 100 μl PBS + 32 mM EDTA + 0.1% Triton X-100 + 500 μM ATP, containing 1 mg SPA beads. Then a volume of 110 μl is transferred to Optiplate.
After 20 min. incubation for substrate capture, lOQμl 5M CsCl were added to allow statification of beads to the top ofthe Optiplate and let stand 4 hours before radioactivity counting in the Top-Count instrument. ICSO determination: see above Inhibition agsay of PICA activity
Kinase reaction: 10 μM in house biotinylated histone HI (Sigma # H-5505) substrate, 10 μM ATP (0.2 microM P33γ-ΛTP), 0.45 U PKA (Sigma # 2645), inhibitor in a final volume of 30 μl buffer (TRIS HCl 10 mM pH 7.5, MgCl2 10 mM, DTT 7.5 mM + 0.2 mg ml BSA) were added to each well of a 96 U bottom. After 90 min at r.t. incubation, reaction was stopped by 100 μl PBS + 32 mM EDTA + 0.1% Triton X-100 + 500 μM ATP, containing 1 mg SPA beads. Then a volume of 110 μl is transferred to Optiplate. After 20 min. incubation for substrate capture, 100μl 5M CsCl were added to aUow statification of beads to the top ofthe Optiplate and let stand 4 hours before radioactivity counting in the Top-Count instrument. IC50 determination: see above Inhibition assay of EGFR activity
Kinase reaction: 10 μM in house biotinylated MBP (Sigma # M-1891) substrate, 2 μM ATP (0.04 microCi P3 γ-ATP), 36 ng insect cell expressed GST-EGFR, inhibitor in a final volume of 30 μl buffer (Hepes 50 mM pH 7.5, MgCl2 3 M, MnCl2 3 mM, DTT 1 mM, NaV03 3μM + 0.2 mg/ml BSA) were added to each well of a 96 U bottom. After 20 min at r.t. incubation, reaction was stopped by 100 μl PBS + 32 mM EDTA + 0.1% Triton X-100 + 500 μM ATP, containing 1 mg SPA beads. Then a volume of 110 μl is transferred to Optiplate. After 20 min. incubation for substrate capture, 100μl 5M CsCl were added to aUow statification of beads to the top ofthe Optiplate and let stand 4 hours before radioactivity counting in the Top-Count instrument. IC50 determination: see above Inhibition assay of IGFl-R activity The inhibition assay of IGFl-R activity was performed according to the following protocol.
Kinase reaction: 10 μM biotinylated MBP (Sigma cat. # M-1891) substrate, 0-20 μM inhibitor, 6 μM ATP, 1 microCi 33P-ATP, and 22.5 ng GST-IGF1-R (pre-incubated for 30 min at room temperature with cold 60 μM cold ATP) in a final volume of 30 μl buffer (50 mM HEPES pH 7.9, 3 mM MnCl2, 1 mM DTT, 3 μM NaV03) were added to each weU of a 96 U bottom well plate. After incubation for 35 min at room temperature, the reaction was stopped by addition of 100 μl PBS buffer containing 32 mM EDTA, 500 μM cold ATP, 0.1% Triton X100 and lOmg/ml streptavidin coated SPA beads. After 20 min incubation, 110 μL of suspension were withdrawn and transferred into 96-weU
OPTIPLATEs containing 100 μl of 5M CsCl. After 4 hours, the plates were read for 2 min in a Packard TOP-Count radioactivity reader.
Inhibition assay of Aurora-2 activity
Kinase reaction: 8 μM biotinylated peptide (4 repeats of LRRWSLG), 10 μM ATP (0.5 uCi P33γ-ATP), 15 ng Aurora2, inhibitor in a final volume of 30 μl buffer (HEPES 50 mM pH 7.0, MgCl2 10 mM, 1 mM DTT, 0.2 mg/ml BSA, 3μM orthovanadate) were added to each well of a 96 U bottom well plate. After 30 minutes at room temperature incubation, reaction was stopped and biotinylated peptide captured by adding 100 μl of bead suspension.
Stratification : 100 μl of CsC12 5 M were added to each well and let stand 4 hour before radioactivity was counted in the Top-Count instrument. IC50 determination: see above
Inhibition assay of Cdc7/dbf4 activity
The inhibition assay of Cdc7/dbf4 activity was performed according to the following protocol.
The Biotin-MCM2 substrate is trans-phosphorylated by the Cdc7/Dbf4 complex in the presence of ATP traced with γ^-ΛTP. The phosphorylated Biotin-MCM2 substrate is then captured by Streptavidin-coated SPA beads and the extent of phosphorylation evaluated by β counting.
The inhibition assay of Cdc7/dbf4 activity was performed in 96 wells plate according to the following protocol. To each well of the plate were added:
- 10 μl substrate (biotinylated MCM2, 6 μM final concentration) 10 μl enzyme (Cdc7 Dbf4, 12.5 nM final concentration)
- 10 μl test compound (12 increasing concentrations in the nM to μM range to generate a dose-response curve) - 10 μl of a mixture of cold ATP (lOμM final concentration) and radioactive ATP (1/2500 molar ratio with cold ATP) was then used to start the reaction which was allowed to take place at 37°C.
Substrate, enzyme and ATP were diluted in 50 mM HEPES pH 7.9 containing 15 mM MgCl2, 2 mM DTT, 3 μM NaVG3, 2mM glycerophosphate and 0.2mg/ml BSA. The solvent for test compounds also contained 10% DMSO.
After incubation for 20 minutes, the reaction was stopped by adding to each well 100 μl of PBS pH 7.4 containing 50 mM EDTA, 1 mM cold ATP, 0.1% Triton XI 00 and 10 mg/ml streptavidin coated SPA beads. After 15 minutes of incubation at room temperature to allow the biotinylated MCM2- streptavidin SPA beads interaction to occur, beads were trapped in a 96 wells filter plate
(ϋnifilterR GF/B™) using a Packard Cell Harvester (Filtermate), washed with distilled water and then counted using a Top Count (Packard).
Counts were blank-subtracted and then the experimental data (each point in triplicate) were analyzed for IC50 determination using a non-linear regression analysis (Sigma
Plot).
Given the above inhibition assays, the compounds of formula (I) ofthe invention resulted to possess a remarkable kinase inhibitory activity.
See, as an example, the following experimental data, (IC50) of two representative compounds of the invention of formula (I) being tested against Cdk2/Cyclin A:
3-(4-tert-butyl-benzamido)-5-[(2-propy]amino)pyrimidin-4-yl]-4,6-dihydropyrrolo[3,4- cjpyrazole (IC50 0.22 μM); and
3-(4-tert-butyl-benzamido)-5-[2-(N-morρholino)pyr__midin-4-yl]-4,6-dihydropyrrolo[3,4- cjpyrazole (IC50 0.34 μM). Surprisingly, their inhibitory activity resulted to be markedly superior than that of the prior art compounds of WO 02/12242 (reference compounds), being used for comparative purpose and tested against Cdk2/Cyclin A as above reported. Reference Compound: N-{5-(pyridine-4-carbonyl)-4,6-dihydropyrrolo[3,4-c]pyrazol-3-yl}-4- tertbutylbenzamide (IC50 >10 μM), [see WO 02/12242 on page 143, lines 29-32]; and N-{5-(pyrazine-2-carbonyl)-4,6-dihydropyrrolo[3,4-c]pyrazol-3-yl}-4- tertbutylbenzamide (IC502.5 μM), [see WO 02/12242 on page 144, lines 5-8]. So far, the novel compounds of the invention are unexpectedly endowed with a cdk inhibitory activity significantly higher than that of the structurally closest prior art compounds of WO 02/12242 and are thus particularly advantageous, in therapy, against proliferative disorders associated with an altered ceU cycle dependent Idnase activity. The compounds of formula (I) of the present invention, suitable for administration to a mammal, e.g. to humans, can be administered by the usual routes and the dosage level depends upon the age, weight, conditions ofthe patient and the administration route. For example, a suitable dosage adopted for oral administration of a compound of formula (I) may range from about 10 to about 500 mgpro dose, from 1 to 5 times daily. The compounds of the invention can be administered in a variety of dosage forms, e.g. orally, in the form of tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in the form of suppositories; parenteraUy, e.g. intramuscularly, or by intravenous and/or intrathecal and or intraspinal injection or infusion.
In addition, the compounds of the invention can be administered either as single agents or, alternatively, in combination with known anticancer treatments such as radiation therapy or chemotherapy regimen in combination with cytostatic or cytotoxic agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), metallomatrixprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-growth factor receptor agents, anti-HER agents, anti-EGFR agents, anti- angiogenesis agents, farnesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, cell cycle inhibitors, other cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors and the like, optionally within liposomal formulations thereof.
If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described above and the other pharmaceutically active agent within the approved dosage range. Compounds of formula (I) may be used sequentially with known anticancer agents when a combination formulation is inappropriate. The present invention also includes pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable excipient (which can be a carrier or a diluent). The pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.
For example, the solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, sucrose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gum, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. a starch, alginic, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents such as lecithin, polysorbates, laurylsulfates; and, in general, non-toxic and pharmacologicaUy inactive substances used in pharmaceutical formulations. Said pharmaceutical preparations may be manufectured according to known techniques, for example by means of mixing, granulating, tabletting, sugar- coating, or film-coating processes.
The liquid dispersions for oral administration may be, e.g., syrups, emulsions and suspensions. The syrups may contain as carrier, for example, saccharose or saccharose with glycerin and/or mannitol and/or sorbitol.
The suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylceUulose, or polyvinyl alcohol. The suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride. The solutions for intravenous injections or infusions may contain as a carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions or they may contain as a carrier propylene glycol. The suppositories may contain together with the active compound a pharmaceutically acceptable carrier, e.g. cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty ester surfactant or lecithin.
The following examples are herewith intended to better illustrate the present invention without posing any limitation to it.
General methods
HPLC Conditions
Instrumentation: Waters 2795 HPLC system equipped with a 996 Waters PDA detector and Micromass mod. ZQ single quadrupole mass spectrometer, equipped with an electrospray (ESI) ion source.
Chromatographic condition: KP18 Waters X Terra (4,6 x 50 mm, 3.5 μm) column;
Mobile phase A was ammonium acetate 5 mM buffer (pH 5.5 with acetic acid/acetonitrile 95:5), and Mobile phase B was H20/acetonitrile (5:95). Gradient from
10 to 90% B in 8 minutes, hold 90% B 2 minutes. UV detection at 220 nm and 254 nm. Flow rate 1 ml/min. Injection volume 10 μl. Full scan, mass range from 100 to 800 amu.
CapiUary voltage was 2.5 KV; source temperature was 120°C; cone was 10 V. Retention times (HPLC r.t.) are given in minutes at 220 nm or at 254 nm. Mass are given as m z ratio.
As formerly indicated, several compounds of formula (I) of the invention have been synthesized in parallel, according to combinatorial or parallel chemistry techniques and purified, when necessary, using parallel purification techniques.
In this respect, some compounds thus prepared have been conveniently and unambiguously identified with HPLC retention time and mass.
Example 1 Preparation of 3-amino-5-tert-butyloxycarbonyI-l-ethoxycarbonyl-4,6- dihydropyrrolo[3,4-c]pyrazole
A solution of ethyl chlorocarbonate (8.9 ml, 93 mmol) in THF (250 ml) was added slowly to a mixture of 3-an__mo-4,6-dihydro-lH-pyrrolo[3,4-c]pyrazole-5-carboxylic acid tert-butyl ester (20 g, 89 mmol) and diisopropylethylamine (DIEA, 92 ml, 528 mmol) in THF (500 ml) at 0-5°C. The reaction was kept at the same temperature for two hours then allowed to reach room temperature and stirred overnight. The obtained mixture was evaporated to dryness under vacuum. The resulting residue was extracted with ethyl acetate and water. The organic phase was separated, dried over sodium sulfate and evaporated to dryness. The mixture was purified by flash-chromatography (eluent: ethyl acetate/cyclohexane 4/6 to 7/3) to give 19 g (72% yield) ofthe title compound as a white soUd.
1H-NMR (400 MHz, DMSO-δ6) ppm: 10.06 (s, broad signal, 2H), 4.4-4.05 (m, 6H), 1.27 (t, 3H) 1 (2, 9H).
Example 2 Preparation of 3-amino-l-ethoxycarbonyl-4,6-dihydropyrroIo[3,4-c]pyrazole 3-A_mino-5-tert-bu1yloxycarbonyl-l-e1hoxycarbonyl-4,6-dihydropyrrolo[3,4-c]pyrazole (1 g, 3.37 mmol) was treated with 4N HCl in 1,4-dioxane (20 eq.) and dichloromethane (50 ml) at room temperature for about 2 hours. After evaporation of the solvents, the crude material was triturated with diethyl ether, filtered and dried under vacuum to yield the title compound as the hydrochloric acid salt which was used without any further purification (colourless solid, quantitative yield).
1H-NMR (400 MHz, DMSO-56) ppm: 10.06 (s, broad signal, 2H), 4.38-4.08 (m, 6H),
1.27 (t, 3H).
By operating in an analogous way the following compounds were also obtained:
3-[4-(morphoIin-l-yl)-benzamido]-l-ethoxycarbonyl-4,6-dihydropyrrolo[3,4- cjpyrazole
1H-NMR (400 MHz, DMSO-56) ppm: 11.33 (s, broad signal, 2H), 10.10 (m, broad signal, IH), 7.97 (m, 2H), 7.02 (m, 2H), 4.49-4.42 (m, 6H), 3.75-3.29 (m, 8H), 1.36 (t, 3H); 3-[4-(N-mcthyl-pipcrazin-l-yl)-bcnzamido]-l-cthoxycarbonyl-4,6- dihydropyrrolo[3,4-c]pyrazolc lH-NMR (400 MHz, DMSO-δ6) ppm: 11.38 (s, broad signal, 2H), 10.26 (m, broad signal, IH), 8.00 (m, 2H), 7.10 (m, 2H), 4.56-4.42 (m, 6H), 4.06-3.22(m, 8H), 2.83 (m, 3H), 1.37 (t, 3H).
Example 3 Preparation of 3-amino-l-ethoxycarbonyl-5-[(2-methylthio)pyrimidin-4-yl]-4,6- dihydropyrrolo [3,4-c]pyrazole 2-Methylthio-4-chloropyrimidine (0.019 ml, 0.16 mmol) and K2C03 (33 mg, 0.24 mmol) were added to a solution of 3-amino-l-ethoxycarbonyl-4,6-dihydropyrrolo[3,4- c]pyrazole (50 mg, 0.16 mmol) in DMSO (1 ml), being prepared according to the example 2. The mixture was heated at 90°C for 4 hours. Water (30 ml) was added and the mixture was extracted with ethyl acetate (2 x 20 ml). The organic layers were combined, washed with brine, dried over sodium sulfate, filtered and dried under vacuum. The crude material was purified by flash chromatography on sUica gel, using cyclohexane:ethyl acetate as eluent, to yield the title compound as a white solid (25 mg, yield 80%). IH-NMR (400 MHz, DMSO-56) ppm: 8.09-8.02 (m, IH), 6.34-6.16 (m, IH), 4.77-4.21
(m, 4H), 4.33-4.21 (q, 2H, J=7.07Hz), 2.44 (s, 3H), 1.33-1.23 (t, 3H, J=7.07Hz).
Example 4
Preparation of 3-amino-l-ethoxycarbonyl-5-[(2-chloro)pyrimidin-4-yl]-4,6- dihydropyrroIo[3,4-c]pyrazoIe 2,4-Dichloropyrimidine (4.11 g, 18.3 mmol) and diisopropylethyl amine (9.8 ml, 54.9 mmol) were added to a suspension of 3-amino-l-ethoxycarbonyl-4,6- dihydroρyrrolo[3,4-c]ρyrazole dihydrochloride (4.89 mg, 18.3 mmol) in isopropanol
(iPrOH, 300 ml), being prepared according to the example 2.
The mixture was heated at reflux for 7 hours and then it was allowed to cool to room temperature. The title compound was obtained as a beige powder upon filtration of the reaction mixture and it was used without any further purification (5.27 g).
IH-NMR (400 MHz, DMSO-56) ppm: 6.6 (d, IH), 6.45 (d, IH), 5.77 (s, bs, 2H), 4.65
(m, 2H), 4.27 (m, 4H), 1.25 (t, 3H).
By operating in an analogous way the following compounds were also obtained: 3- [4-(morpholin-l-yl)-bcnzamido] -l-ethoxycarbonyI-5- [(2-chloro)pyrimidin-4-yl] -
4,6-dihydropyrroIo [3,4-c]pyrazole
IH-NMR (400 MHz, DMSO-δ6) ppm: 11.22 (s, IH), 8.13 (d, IH), 7.98 (d, 2H), 6.96
(d, 2H), 6.62(d, IH), 4.8-4.6 (m, 4H), 4.4 (q, 2H), 3.72 (m, 4 H), 3.25 (m, 4H), 2.35 (t,
3H). 3-[4-(N-methyl-piperazin-l-yl)-benzanιido]-l-ethoxycarbonyl-S-[(2- chioro)pyrimidin-4-yl]-4,6-dihydropyrrolo[3,4-c]pyrazoIe [M+Hf 511.19; r.t. 4.11 min.
Example 5 Preparation ©f 3-(tert-butyl-benκamido)-l-ethoxycarbonyl-5-[(2- methylthio)ρyrimidin-4-yl]-4,6-diIιy ropyrrollo[3,4-e]ρyτazole Tri-(2-aminoethyl)-amine polystirene (6 g, 18.7 mmol) was added to a solution of 3- amino- 1 -e1hoxycarbonyl-5-[(2-methylthio)pyrimidin-4-yl] -4, 6-dihydropyrrolo[3 ,4- c]ρyrazole (1.2 g, 3.74 mmol) in dry THF (120 ml). 4-Tert-butyl-benzoyl chloride (6 mmol) was added dropwise to the suspension. The mixture was stirred at room temperature for 24 hours. The suspension was filtered, washed with tetiahydrofuran and dichloromethane. After evaporation of the solvents, water was added and the mixture was extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over sodium sulfate, filtered and dried under vacuum. The crude material was purified by flash chromatography on silica gel, using cyclohexane:ethyl acetate as eluent, to yield the title compound (1.07 g, 70%). IH-NMR (400 MHz, DMSO-56) ppm: 11.68-11.19 (m, IH), 8.12-8.24 (m, IH), 8.04- 7.97 (m, 3H), 7.54-7.49 (m, 2H), 6.41-6.27 (m, IH), 4.92-4.58 (m, 4H), 4.50-4.32 (q, 2H, J=7.07Hz), 2.45 (s, 3H), 1.43-1.26 (m, 12H).
By operating in an analogous way the following compounds were also obtained: l-ethoxycarbonyl-3-(4-fluoro-benzamido)-5-[(2-methylthio)pyrimidin-4-yl]-4,6- dihydroρyrrolo[3,4-c]pyrazoIe (71% yield)
IH-NMR (400 MHz, DMSO-56) ppm: 11.58 ( , IH), 8.18-8.10 (m, 2H), 8.09-8.03 (m, IH), 7.37-7.29(m, 2H), 6.38-6.27( m, IH), 4.92-4.58 (m, 4H), 4.46-4.37 (q, 2H, J=7.07Hz), 2.45 (s, 3H), 1.41-1.31 (t, 3H, J=7.07Hz); l-ethoxycarbonyl-3-(4-fluoro-benzamido)-5-[(2-methanesuIfonyl)pyrimidin-4-yl]- 4,6-dihydropyrrolo [3,4-c]p yr azole
IH-NMR (400 MHz, DMSO-δ6) ppm: 11.66 (m, IH), 8.47-8.33 (dd, IH, J=5.86Hz, J=2.20Hz), 8.28-8.09 (m, 2H), 7.46-7.30 (m, 2H), 6.99-6.82 (m, IH), 5.04-4.75 (m, 4H), 4.57-4.36 (m, 2H), 3.34 (s, 3H), 1.48-1.32 (m, 3H); l-ethoxycarbonyl-3-(3-phenoxy-bcnzamido)-5-[(2-methyIthio)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole (80% yield) IH-NMR (400 MHz, DMSO-δ6) ppm: 11.68-11.53 (m, IH), 8.15-8.05 (m, IH), 7.91- 7.85 (d, IH, J=7.92Hz), 7.73-7.64 (m, IH), 7.60-7.53 (ID, IH), 7.49-7.43 (m, 2H), 7.34- 7.26 (m, IH), 7.26-7.18 (m, IH), 7.12-7.06 (m, 2H), 6.41-6.31 (m, IH), 4.96-4.62 (m, 4H), 4.49-4,07 (q, 2H, J=7.07Hz), 2.48 (s, 3H), 1.45-1.33 (t, 3H, J=7.07Hz); l-etho_sycarbonyl-3-(2-naphthylacetamido)-5-[(2-methylthio)pyriniidin-4-yl]-4,6- dihydropyrrolo [3,4-e]pyra2θIe
IH-NMR (400 MHz, DMSO-δ6) ppm: 11.55-11.28 (m, IH), 8.10-7.96 (m, IH), 7.91- 7.85 (m, 3H), 7.84-7.79 (m, IH), 7.54-7.43 (m, 3H), 6.39-6.18 (m, IH), 4.85-4.46 (m, 4H), 4.44-4.34 (q, 2H, J=7.08Hz), 3.83 (s, 2H), 2.43 (s, 3H), 1.40-1.28 (t, 3H). 3-[4-(morpho__in-l-yI)-benzamido]-l-ethoxycarbonyl-5-t-butyIoxycarbonyI-4,6- dihydropyrroIo[3,4-c]pyrazole
IH-NMR (400 MHz, DMSO-56) ppm: 11.16 (s, bs,lH), 7.98-7.01 (m, 4H), 4.85-4.46 (m, 4H), 4.55-4.42 (m, 6H), 3.36-2.48 (m, 8H), 2.27 (s, 3H), 1.50 (s, 9H), 1.37 (t,3H); 3-[4-(N-mcthyl-pipcrazin-l-yl)-bcnzamido]-l-ethoxycarbonyl-5-t- butyloxycarbonyl-4,6-dihydropyrroio[3,4-c]pyrazole
IH-NMR (400 MHz, DMSO-56) ppm: 11.14 (s, bs, IH), 7.95-6.95 (m, 4H), 4.50 (m, 4H), 4.38 (q, 3H), 3.72-3.70 (m, 4H), 3.28-3.23 (m, 4H), 1.44 (s, 9H), 1.32 (t,3H).
Example 6 Preparation of 3-cyclobutanoylamido-l-ethoxycarbonyI-5-[(2-chIoro)pyrimidnι-4- yI]-4,6-dihydropyrrolo[3,4-c]pyrazole
Cyclobutanoyl chloride (19 ml, 17.03 mmol) was added to a suspension of 3-amino-l- ethoxycarbonyl-5-[(2-cHoro)pyr__mi(_lin-4-yl]-4,6-d__hydroρyrrolo[3,4-c]pyrazole dihydrochloride (3.5 g, 11.35 mmol) in dry THF (220 ml) and dry pyridine (75 ml). The mixture was stirred at room temperature for 24 hours. The solvents were evaporated and the residue was taken up in hot water (75 ml), stirred for about 30 minutes, filtered, washed with diethyl ether and dried under vacuum at 30°C. The title compound was obtained as a beige powder (4.2 g, 95%).
IH-NMR (400 MHz, DMSO-56) ppm: 10.94 (s IH), 8.15 (d, 2H), 6.67 (d, IH), 4.87- 4.58 (m, 4 H), 4.42 (q, 2H), 3.34 (m,lH), 2.43-1.71 (m, 6H), 1.37 (t, 3H). By operating in an analogous way the following compounds were also obtained: 3-(t en-2-yl)-carbo3amido-l-etho_^earbonyl-5-[(2-chloro)pyrimidin-4-yl]-4,6- fiihydropyrrolo[3,4-e]pyrazole
IH-NMR (400 MHz, DMSO-56) ppm: 11.3 (s IH), 8.15 (2, IH), 8.13-7.22 (m, 3H), 6
(d, IH), 4.8-4.6 (m, 4 H), 4.4 (q, 2H), 1.2 (t, 3H); 3-(4-methoxybenzamido)-l-ethoxyearbonyI-S-[(2-chloro)pyriπιid-U_ι-4-yl]-4,6- dihydropyrroIo[3,4-c]pyrazo!e
IH-NMR (400 MHz, DMSO-δ6) ppm: 11.38 (s IH), 8.07 (m, 3H), 7.0 (d, 2H), 6.61 (d,
IH), 4.8-4.66 (m, 4 H), 4.4 (q, 2H), 1.17 ft 3H).
Example 7 l-ethoxycarbonyl-3-(4-fluoro-benzamido)-5-[(2-methanesulfonyl)pyrimid__n-4-yl]-
4,6-dihydropyrrolo [3,4-c]pyr azole m-Chloroperbenzoic acid (2 eq.) was added to a suspension of l-ethoxycarbonyl-3-(4- fluoro-benzamido)-5-[(2-methyltMo)pyrimid__n-4-yl]-4,6-d__hydropyrrolo[3,4-c]pyrazole
(100 mg, 1 eq.) in dichloromethane (25 ml). The mixture was stirred for 1 hour at room temperature then washed with water, 10% sodium thiosulfate, brine, dried over sodium sulfate and evaporated under vacuum. The crude was chromatographed on silica gel, using dichloromethane:ethyl acetate as eluent, to yield the title compound as a colorless powder (55% yield).
IH-NMR (400 MHz, DMSO-56) ppm: 11.66 (m, IH), 8.47-8.33 (dd, IH, J=5.86Hz, J=2.20Hz), 8.28-8.09 (m, 2H), 7.46-7.30 (m, 2H), 6.99-6.82 (m, IH), 5.04-4.75 (m,
4H), 4.57-4.36 (m, 2H), 3.34 (s, 3H), 1.48-1.32 (m, 3H).
Example 8
Preparation of 3-(4-tcrt-butyl-bcnzamido)-5-[(2-methyIthio)pyrimidin-4-yI]-4,6- dihydropyrrolo [3,4-c]pyrazoIe A solution of 3-(tert-butylbenzamido)-l-ethoxycarbonyl-5-[(2-methyltMo)pyrimidin-4- yl]-4,6- dihydroρyrrolo[3,4-c]ρyrazole (3.7 mmol) in methanol (15 ml) and triethylamine
(1 ml), was stirred at 40°C for 4 hours. After evaporation of the solvents, the solid was washed with diethyl ether and dried so as to obtain the title compound (yield 100 %)
IH-NMR (400 MHz, DMSO-56) ppm: 12.48 (m, IH), 10.87 (m, IH), 8.12-8.04 (m, IH), 8.02-7.86 (m, 2H), 7.66-7.42 (m, 2H), 6.39-6.28 (m, IH), 4.87-4.42 (m, 4H), 2.49
(s, 3H), 1.34 (s, 9H). Operating in an analogous way, the following compounds were also obtained:
3-(4-fluoro-benzanndo)-5-[(2-methylthio)pyr__mid__n-4-yl]-4,6-d__hydropyrrolo[3,4- cjpyrazofc
IH-NMR (400 MHz, DMSO-d6) ppm: 12.51 (m, IH), 11.00 (m, IH), 8.18-7.96 (m, 3H), 7.47-7.24 (m, 2H), 6.42-6.28 (m, IH), 4.85- .28 (m, 4H), 2.49 (s, 3H);
3-(3-phenoxy-ben_2amido)-S-[(2-metlιyIthio)pyriπιidin-4-yl]-4,6- dihydropyrroIo[3,4-c]pyrazole
IH-NMR (400 MHz, DMSO-56) ppm: 12.50 (m, IH), 11.04 (m, IH), 8.11-8.02 (m,
IH), 7.86-7.78 (m, IH), 7.70-7.61 (m, IH), 7.59-7.52 (m, IH), 7.49-7.42 (m, 2H), 7.31- 7.25 (m, IH), 7.24-7.18 ft IH, J=7.31Hz), 7.12-7.07 (m, 2H), 6.38-6.31 (m, IH), 4.76-
4.46 (m, 4H), 2.48 (s, 3H).
Example 9
Preparation of 3-(4-tert-butyl-bcnzamido)-l-polystyrcnctrityI-5-[(2- mcthyIthio)pyrimidin-4-yl]- 4,6-dihydropyrrolo[3,4-c]pyrazolc Trityl chloride resin (1.76 g, loading 1.27 mmol/g) was sweUed with 10 ml of dichloromethane. A solution of 3-(tert-bu1ylbenzaιmdo)-5-[(2-methyltMo)ρyrimidin-4- yl]-4,6-dihydropyrrolo[3,4-c]pyrazole (1 g, 2.62 mmol) in 40 ml of dimethylformamide was added therein.
The mixture was stirred at room temperature for 48 hours. After filtration, the resin was washed with dichloromethane (2 x 20 ml), MeOH (2 x 20 ml), dimethylformamide (2 x
20 ml) dichloromethane (3 x 20 ml) and diethyl ether (2 x 20 ml). The resin supporting the title compound was dried under vacuum (loading 50%).
By operating in an analogous way, the following compounds may be also obtained:
3-(4-fluoro-bcnzamido)-l-polystyrcnetrityl-5-[(2-mcthylthio)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazolc;
3-(3-phenoxy-benzamido)-l-poIystyrenetrityl-5-[(2-methylthio)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole.
Example 10
Preparation of 3-(4-tert-butyI-benzamido)-l-polystyrenetrityl-5-[(2- methanesulfonyI)pyrimidin-4-yl]- 4,6-dihydropyrroIo[3,4-c]pyrazole A solution of m-chloroperbenzoic acid NaOH (1/1) in dioxane, was added dropwise to
3-(4-tert-butyl-tenzamido)-l-polystyrenetrityl-5-[(2-memylt o)pyrimidin-4-yl]- dihydroρyrrolo[3,4-c]pyrazole. The mixture was stirred for 1 hour at room temperature.
After filtration, the resin was washed with dichloromethane (2 x 20 ml), MeOH (2 x 20 ml), dimethylformamide (2 x 20 ml), dichloromethane (3 x 20 ml) and diethyl ether (2 x
20 ml) and dried under vacuum, yielding the title compound.
By operating in an analogous way, the foUowing compounds may be also obtained:
3-(4-fluoro-benzamido)-l-polystyrenetrityl-5-[(2-methanesulfonyl)pyrimidin-4-yl]-
4,6-dihydropyrroIo[3,4-c]pyrazole; 3-(3-phenoxy-benzamido)-l-polystyrenetrityl-5-[(2-methanesu__fonyl)pvrlmidin-4- yl]-4,6-dihydropyrrolo[3,4-c]pyrazoIe.
Example 11
Preparation of 3-(4-tert-butyl-bcnzamido)-l-polystyrenctrityl-5-[(2- propylamino)pyrimidin-4-yI]- 4,6-dihydropyrroIo[3,4-c]pyrazolc Propylamine (30 eq.) was added to a suspension of 3-(4-tert-butyl-benzaιnido)-l- polystyrenetrityl-5-[(2-memanesdfonyl)pyrire d__n-4-yl]-4,6-dihydropy^ c]pyrazole (0.975 g, 0.57 mmol), in dioxane (3 ml). The mixture was stirred for 20 hours at 80°C. After filtration, the resin was washed with dichloromethane (2 x 20 ml), MeOH
(2 x 20 ml), dimethylformamide (2 x 20 ml), dichloromethane (3 x 20 ml) and diethyl ether (2 x 20 ml). Then, the resin was dried under vacuum affording the title compound.
By operating in an analogous way and by using a suitable amine, the following compounds may be also obtained:
3-(4-fluoro-bcnzamido)-l-polystyrcnctrityl-5-[(2-propylamino)pyrimidin-4-yl]-4,6- dihydr opyrrolo [3,4-c]pyrazole; 3-(3-phenoxy-benzamido)-l-polystyrenetrityl-5-[(2-propylamino)pyrimidin-4-yl]-
4,6-dihydropyrrolo[3,4-c]pyrazole;
3-(4-fluoro-benzan_ύdo)-l-polystyrenetrityl-5-[(2-benzylamino)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole;
3-(4-tcrt-butyI-benzamido)-l-poIystyrcnctrityl-5-[(2-benzylamino)pyrimidin-4-yl]- 4,6-dihydropyrrolo[3,4-c]pyrazole; 3-(3-pheno_^-benaan__idffl)-l-poϊystyreneMtyI-5-[(2-ben___ylamύιo)pyrimidin-4-yl]-
4,6-dihydropyrrolo[3,4-c]pyrazoIe;
3-(4-fluoro-benzamido)-l-poIystyreneWtyl-S-[2-(K-mo- ho____nffl)pyrinιidin-4-yl]-
4,6-d__hydropyrrolo[3,4-c]pyraEθIe; 3-(4-te-rt-butyl-bensamido)-l-poIystyreneMtyl-5-[2-(T_iJ-morphoIino)pyrimidin-4- yl]- 4,6-dihydropyrrolo[3,4-c]pyraEθIe;
3-(3-phenoxy-benzamido)-l-poIystyrenetrityI-5-[2-(N-morpholino)pyrimidin-4-yl]-
4,6-dihydropyrrolo [3,4-c]pyrazoIe;
3-(4-fluoro-benzamido)-l-polystyrenetrityI-5-[2-(4-methyl-piperazino) pyrimidin- 4-yl]- 4,6-dihydropyrrolo[3,4-c]pyraz»le;
3-(4-tert-butyI-benzamido)-l-poIystyrcnctrityl-5-[2-(4-mcthyl- pipcrazino)pyrimidin-4-yl]- 4,6-dihydropyrrolo[3,4-c]pyrazolc;
3-(3-phenoxy-benzamido)-l-polystyrcnetrityl-S-[2-(4-mcthyl-pipcraz__no)pyrimidin-
4-yl]-4,6-dihydropyrrolo[3,4-c]pyrazole; 3-(4-fluoro-benzamido)-l-poIystyrenetrityl-S-[2-(4-methyl-piperidino) pyrimidin-4- yI]- 4,6-dihydropyrroIo[3,4-c]pyrazole;
3-(4-tert-butyl-benzamido)-l-poIystyrenetrityl-5-[2-(4-methyI- piperidino)pyr__midin-4-yI]- 4,6-dihydropyrroIo[3,4-c]pyrazole;
3-(3-phenoxy-benzamido)-l-polystyrcnetrityl-S-[2-(4-methyl-piperidino)pyrimidin- 4-yl]-4,6-dihydropyrroIo[3,4-c]pyrazole;
3-(4-fluoro-benzaπύdo)-l-polystyrenetrityl-5-[2-(4-dimethyl ethylendiamino) pyrimidin-4-yl]- 4,6-dihydropyrrolo[3,4-c]pyrazolc;
3-(4-tcrt-butyI-bcnzamido)-l-poIystyrenctriryl-5-[2-(4-dimcthyI-ethylcndiaπιino) pyrimidin-4-yl]- 4,6-d__hydropyrroIo[3,4-c]pyrazole; 3-(3-phenoxy-benzamido)-l-polystyrenetrityl-5-[2-(4-dimethyI-ethylendiamino) pyrimidin-4-yl]-4,6-d__hydropyrrolo[3,4-c]pyrazole;
3-(4-fluoro-benzaπύdo)-l-polystyreneWtyI-5-[2-(l,4-Wmethyl-ethylendiamino) pyrimidin-4-yl]- 4,6-d__hydropyrrolo[3,4-c]pyrazoIe;
3-(4-tcrt-butyl-benzamido)-l-polystyrenctrityl-5-[2-(l,4-trimethyI-ethyIcndiamino) pyrimidin-4-yl]- 4,6-dihydropyrrolo[3,4-c]pyrazole;
3-(3-phenoxy-benzamido)-l-poIystyrenetrityI-5-[2-(l,4-trimethyI-ethyIendiamino) pyrimidin-4-yI]-4,6-dihydropyrrolo[3,4-c]pyrazole;
3-(4-fluoro-benzamido)-l-polystyrenetrityl-S-[2-(4-hydro_symethyl iperidino) pyrimidin-4-yl]- 4 ,6-dihydropyrrolo [3,4-c]pyrazoIe;
3-(4-tert-butyl-be_____zamido)-l-poIystyrenetrityI-S-[2-(4- hydrosyπιethyI piperidino)pyrimϊdin-4-yl]- 4,6-dihydropyrroIo[3,4-c]pyrazole;
3-(3-pheno_sy-ben_zamido)-l-poIystyrenetrityI-5-[2-(4- hydro_symethyl piperidino)pyrimidin-4-yl]-4,6-dihydropyrrolo[3,4-e]pyrazole;
3-(4-fluoro-benzamido)-l-poIystyrenetrityl-5-{2-[4-(2-hydroxyethyI)piperazino] pyrimidin-4-yl} 4,6-dihydropyrroIo[3,4-c]pyrazoIe; 3-(4-tert-butyl-benzamido)-l-polystyrenetrityl-5-{2-[4-(2-hydroxyethyI)piperazino] pyrimidin-4-yi}- 4,6-d__hydropyrroIo[3,4-c]pyrazolc;
3-(3-phenoxy-bcnzamido)-l-polystyrenetrityl-5-{2-[4-(2-hydro_s_yethyl)pipcrazino] pyrlmidin-4-yl}-4,6-d__hydropyrrolo[3,4-c]pyrazoIc;
3-(4-flnoro-bcnzamido)-l-polystyrcnetrityl-5-[(2-cyclopropylamino) pyrimidin-4- yl]- 4,6-d__hydropyrrolo[3,4-c]pyrazole;
3-(4-tert-buryI-benzamido)-l-polystyrenetrityl-5-[(2- cycIopropyIamino)pyrimidin-
4-yl]- 4,6-dihydropyrroIo[3,4-c]pyrazole;
3-(3-phenoxy-benzamido)-l-polystyrenetrityl-5-[(2- cycIopropylammo)pyrimidin-
4-yl] -4,6-dihydropyrrolo [3,4-c]ρyr azole. Example 12
Preparation of 3-(4-tert-butyl-benzamido)-l-polystyrcnctrityI-5-[(2- phcnylamino)pyrimidin-4-yl] -4,6-dihydropyrrolo [3,4-c]pyrazole
A suspension of 3-(4-tert-butyl-benzamido)-l-polystyrenetrityl-5-[(2- meflιanesulfonyl)ρyrimidm-4-yl]-4,6-dihydropyrrolo[3,4-c]ρyrazole in neat aniline was placed in a microwave oven for 20 minutes at 140°C.
After filtration, the resin was washed with dichloromethane (2 x 20 ml), MeOH (2 x 20 ml), dimethylformamide (2 x 20 ml) dichloromethane (3 x 20 ml) and diethyl ether (2 x
20 ml). The resin was dried under vacuum affording the title compound.
By operating in an analogous way, the following compounds may be also obtained: 3-(4-fluoro-benzamido)-l-poIystyrenetrityl-5-[(2-phcnylammo) pyrimidin-4-yI]-
4,6-dihydropyrrolo [3,4-c]pyraEθle; 3-(3-pheno_ay-ben__jamido)-l-polystyreneWtyl-S-[(2- phenylam__no)pyrimidin-4-yl]-
4,6-dihydropyrroIo[3,4-c]pyra___»le.
Example 13
Preparation of 3-(4-tert-butyl-ben_zamido)-l-poIystyrenetrityll-S-[(2- ethyIoxy)ρyrimidin-4-yl]-4,6-dihydropyrroIo[3,4-c]ρyrazole
Sodium ethylate (30 eq) was added to a suspension of 3-(4-tert-bufyl-benzamido)-l- ρolystyτenetrityl-5-[(2-memanesulfonyl)pyτ__mid__n-4-yl]-4,6-d__hydropyrrolo[3,4- c]ρyrazole (0.975 g, 0.57 mmol) in dioxane (3 ml). The mixture was stirred for 20 hours at 80°C. After filtration, the resin was washed with dichloromethane (2 x 20 ml), MeOH (2 x 20 ml), dimethylformamide (2 x 20 ml), dichloromethane (3 x 20 ml) and diethyl ether (2 x 20 ml). The resin was dried under vacuum affording the tile compound (yield
30%).
By operating in an analogous way and by using a suitable alcoholate, the following compounds may be also obtained: 3-(4-fluoro-benzamido)-l-polystyrenetrityI-5-[(2-ethyIoxy) pyrimidin-4-yl]- 4,6- dihydropyrrolo[3,4-c]pyrazole;
3-(3-phenoxy-benzamido)-l-poIystyrenetrityI-5-[(2-ethyIoxy)pyrimidin-4-yI]-4,6- dihydropyrrolo[3,4-c]pyrazole;
3-(4-fluoro-benzamido)-l-polystyrcnetrityI-5-[2-(l-methylpipcridin-4-yloxy) pyrimidin-4-yI] - 4,6-dihydropyrrolo [3,4-c]pyrazoIe;
3-(4-tcrt-butyl-benzamido)-l-polystyrenctrityl-5-[2-(l-methylpipcridin-4-yloxy) pyrimidin-4-yl]- 4,6-d__hydropyrrolo[3,4-c]pyrazolc;
3-(3-phenoxy-benzamido)-l-polystyrenctrityl-5-[2-(l-mcthylpiperidin-4-yIoxy) pyrimidin-4-yl]-4,6-dihydropyrrolo[3,4-c]ρyrazoIe. Example 14
Preparation of 3-(4-tert-butyl-benzamido)-5-[(2-propylamino)pyrimidin-4-yI]-4,6- dihydropyrroIo[3,4-c]pyrazole
A solution of trifluoro acetic acid in dichloromethane (20/80) was added to the resin 3-
(4-tert-butyl-benzamido)-l-polystyrenetrifyl-5-[(2-propylarnino)pyrimidin-4-yl]-4,6- dihydropyιrolo[3,4-c]pyrazole. The suspension was stirred for 15 minutes at room temperature. After filtration, the solvent was evaporated and the crude was neutralized with NH4OH and dried under vacuum thus affording the title compound (yield 76%).
IH-NMR (400 MHz, DMSO-56) ppm: 12.38 (m, IH), 10.84 (m, IH), 7.99-7.89 (d, 2H,
J=7.93Hz), 7.81-7.78 (d, IH, J=5.85Hz), 7.56-7.48 (d, 2H, J=7.93Hz), 6.69-6.42 (m, IH), 5.81-5.75 (d, IH, J=5.85Hz), 4.75-4.30 (m, 4H), 3.23-3.14 (m, 2H), 1.60-1.44 (m,
2H), 1.30 (s, 9H), 0.90-0.83 ft 3H, J=7.44Hz).
By operating in an analogous way, the following compounds were also obtained:
3-(4-fluoro-benzamido)-5-[(2-propylamino)pyrimidin-4-yl]-4,6-dihydropyrroIo[3,4- cjpyrazole (yield 90%) IH-NMR (400 MHz, DMSO-56) ppm: 12.46 (m, IH), 10.97 (m, IH), 8.21-7.94 (m,
2H), 7.89-7.71 (d, IH, J=5.85Hz), 7.49-7.24 (m, 2H), 6.83-6.49 (m, IH), 5.94-5.76 (d,
IH, J=5.61Hz), 4.86-4.32 (m, 4H), 3.47-3.05 (m, 2H), 1.66-1.42 (m, 2H), 1.00-0.73 ft
3H, J=7.43 Hz);
3-(3-phenoxy-benzamido)-5- [(2-propylamino)pyrimidin-4-yl] -4,6- dihydropyrrolo[3,4-c]pyrazole (yield 67%)
IH-NMR (400 MHz, DMSO-56) ppm: 12.45 (m, IH), 10.98 (m, IH), 7.92-7.05 (m, lOH), 6.76-6.34 (m, IH), 5.92-5.72 (d, IH, J=5.86Hz), 4.87-4.28 (m, 4H), 3.45-3.05
(m, 2H), 1.65-1.40 (m, 2H), 1.00-0.78 ft 3H, J=7.32Hz);
3-(4-tert-butyI-benzamido)-5-[(2-benzyIamino)pyrimidin-4-yl]-4,6- dihydropyrroIo[3,4-c]pyrazoIe (yield 35%)
IH-NMR (400 MHz, DMSO-56) ppm: 12.41 (m, IH), 10.83 (m, IH), 8.10-7.89 (m,
2H), 7.86-7.78 (d, IH, J=5.85 Hz), 7.64-7.08 (m, 8H), 5.95-5.76 (m, IH), 4.87-4.28 (m,
6H), 1.33 (s, 9H);
3-(4-fluoro-benzamido)-5-[(2-benzylamino)pyrimidin-4-yl]-4,6-dihydropyrrolo[3,4- yrazole (yield 90%)
IH-NMR (400 MHz, DMSO-56) ppm: 12.45 (m, IH), 10.96 (m, IH), 8.24-7.96 (m, 2H), 7.89-7.77 (d, IH, J=5.85Hz), 7.49-7.02 (m, 9H), 5.96-5.74 (m, IH), 4.81-4.31 (m, 6H); 3-(3-phenoxy-benzamido)-5-[(2-ben__!ylamino)pyrimidin-4-yl]-4,6- dihydropyrrolo [3,4-e]ρyrazole (yield 36%) IH-NMR (400 MHz, DMSO-56) ppm: 12.44- (m, IH), 10.98 (m, IH), 7.96-6.98 (m,
16H), 5.95.5.77 (m, IH), 4.84-4.29 (m, 6H);
3-(4-tert-butyI-benzamido)-5-[2-(N-moιphoIino)pyrinιid__n-4-yl]-4,6- dihydropyrrolo[3,4-c]pyraEole (yield 48%) IH-NMR (400 MHz, DMSO-56) ppm: 12.45 (m, IH), 10.87 (m, IH), 8.21-7.84 (m,
3H), 7.65-7.42 (m, 2H), 6.04-5.79 (d, IH, J=5.68Hz), 4.90-4.25 (m, 4H), 3.84-3.57 (m,
8H), 1.34 (s, 9H);
3-(4-fluoro-benzamido)-5-[2-(N-morpho__ino)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazoIc IH-NMR (400 MHz, DMSO-56) ppm: 12.44 (m, IH), 10.96 (m, IH), 8.18-7.99 (m,
2H), 7.94-7.87 (m, 1H),7.43-7.21 (m, 2H), 5.97-5.84 (m, IH), 4.83-4.32 (m, 4H), 3.69-
3.56 (m, 8H);
3-(3-phenoxy-benzamido)-5-[2-(N-morphoUno)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole (yield 57%) IH-NMR (400 MHz, DMSO-56) ppm: 12.47 (m, IH), 11.00 (m, IH), 7.98-7.89 (d, IH,
J=5.73Hz), 7.87-7.18 (m, 8H), 7.14-7.00 (d, 2H, J=7.93Hz), 6.02-5.84 (d, IH,
J=5.73Hz), 4.78-4.38 (m, 4H), 3.75-3.58 (m, 8H);
3-(4-fluoro-benzamido)-5-[2-(4-methyl-piperidino)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole; 3-(4-tert-butyI-benzamido)-5-[2-(4-methyl-piperidino)pyrimidin-4-yl]-4,6- dihydropyrrolo [3,4-c]pyr azole;
3-(3-phenoxy-benzamido)-5-[2-(4-methyl-piperidino)pyrimidin-4-yl]-4,6- dihydropyrrolo [3,4-c]pyr azoic;
3-(4-fluoro-benzamido)-5-[2-(4-mcthyI-piperaz__no)pyrimidin-4-yl]-4,6- dihydropyrrolo [3,4-c]pyrazole;
3-(4-tert-butyl-benzamido)-5-[2-(4-mcthyl-pipcrazino)pyrimidin-4-yi]-4,6- dihydropyrrolo[3,4-c]ρyrazole;
3-(3-phenoxy-benzamido)-5-[2-(4-methyl-piperazino)pyrimidin-4-yl]-4,6- dihydr opyrrolo [3,4-c]pyrazole; 3-(4-fluoro-benzamido)-5-[2-(4-dimethyl ethylendiamino)pyrimidin-4-yl]-4,6- dihydropyrroIo[3,4-c]pyrazoIe; 3-(4-tert-butyl-bensamido)-5-[2-(4-d_urnethyl ethylendiamino)pyrimidin-4-yl]-4,<i- dihydropyrrolo [3,4-e]pyrasole;
3-(3-pheno_sy-ben_zamido)-5-[2-(4-dimethyl ethylendiamino)pyri_aiidin-4-yl]-4,6- dihydropyrroIo[3,4-c]pyraEoIe; 3-(4-fluoro-ben_Eamido)-5-[2-(l,4-trimethyl ethylendiamino)pyrimidin-4-yI]-4,6- diliydropyrrolo [3,4-e]pyrazole;
3-(4-tert-butyI-benzamido)-5-[2-(l,4-tr__methyl ethyIendiamino)pyrimidin-4-yI] -4,6- dihydropyrrolo [3,4-c]pyrazoIe;
3-(3-phenoxy-benzamido)-S-[2-(l,4-trimethyl ethylendiamino)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole;
3-(4-fluoro-benzamido)-5- [2-(4-hydroxymethyl pipcridino)pyrimidin-4-yI] -4,6- dihydropyrroIo[3,4-c]pyrazoIc;
3-(4-tert-buryI-benzamido)-S-[2-(4-hydroxymethyI piperidino)pyrimidm-4-yl]-4,6- dihydropyrrolo [3,4-c]pyrazole; 3-(3-phenoxy-benzamido)-5-[2-(4-hydroxymethyI piperidino)pyrimidin-4-yl]-4,6- dihydropyrrolo [3,4-c]pyrazole;
3-(4-fluoro-benzamido)-5-{2-[4-(2-hydroxyethyl)piperazino] pyr__midin-4-yl}-4,6- dihydropyrroIo[3,4-c]pyrazoIe;
3-(4-tcrt-butyl-bcnzamido)-5-{2-[4-(2-hydroxycthyI)piperazino] pyrimidin-4-yI}- 4,6-dihydropvrrolo[3,4-c]pyrazoIe;
3-(3-phenoxy-bcnzamido)-5-{2-[4-(2-hydroxyethyl)piperazino] pyrimidin-4-yI}-4,6- dihydr opyrrolo [3,4-c]pyrazole;
3-(4-fluoro-benzamido)-5-[(2-cyclopropylamino)pyrimidin-4-yl]-4,6- dihydropyrroIo[3,4-c]pyrazoIe; 3-(4-tert-butyl-benzamido)-5-[(2-cyclopropylamino)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole;
3-(3-phenoxy-benzamido)-5-[(2-cyclopropylaπι__no)pyrimidin-4-yl]-4,6- dihydropyrrolo [3,4-c]pyrazolc
IH-NMR (400 MHz, DMSO-56) ppm: 12.45 (m, IH), 10.99 (m, IH), 8.04-7.04 (m, 10H), 6.93-6.45 (m, IH), 5.96-5.78 (m, IH), 4.90-4.30 (m, 4H), 2.80-2.62 (m, IH),
0.71-0.35 (m, 4H); 3-(4-tert-butyϊ-be_____2amido)-5-[(2-phenylamino)pyιimidin-4-yI]-4,6- dihydropyrrolo[3,4-c]pyra2θIe;
3-(4-fluaro-benzamido)-5- [(2-phenylamino)pyrimidin-4-yl] -4,6-dihydropyrrolo [3,4- cjpyrazolc IH-NMR (400 MHz, DMSO-56) ppm: 12.51(m, IH), 10.99 (m, IH), 9.09 (s, IH), 8.19-
8.08 (m, 2H), 8.04-8.00 (d, IH, J=5.83Hz), 7.89-7.78 (m, 2H), 7.45-7.31 (m, 2H), 7.30-
7.20 (m, 2H), 6.95-6.85 (m, IH), 6.12-5.99 (m, IH), 4,96-4.38 (m, 4H);
3-(3-phenoxy-benzamido)-5-[(2-phenylamino)pyrimidin-4-yl]-4,6- dihydr opyrrolo [3,4-c]ρyrazole; 3-(4-fluoro-benzamido)-5-[(2-ethyIoxy)pyrimidin-4-yl]-4,6-dihydropyrrolo[3,4- c]pyrazole;
3-(4-tcrt-butyl-bcnzamido)-5-[(2-cthylo_!ςy)pyrinιid__n-4-yl]-4,6-dihydropyrrolo[3,4- cjpyrazolc;
3-(3-pheπoxy-bcnzamido)-S-[(2-ethyIoxy)pyrimidin-4-yl]-4,6-d__hydropyrroIo[3,4- cjpyrazolc
IH-NMR (400 MHz, DMSO-56) ppm: 12.50 (m, IH), 11.01 (m, IH), 8.09-7.98 (m,
IH), 7.89-7.01 (m, 9H), 6.33-6.13 (m, IH), 4.81-4.43 (m, 4H), 4.37- 4.16 (m, 2H),
1.40-1.21 ft 3H, J=7.07Hz);
3-(4-fluoro-benzamido)-5-[2-(l-methylpiperidin-4-yloxy) pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole:
3-(4-tert-butyl-benzamido)-5-[2-(l-mcthylpiperidin-4-yloxy) pyrimidin-4-yl] -4,6- dihydropyrrolo [3,4-c]pyrazoIc;
3-(3-phenoxy-benzamido)-5-[2-(l-methyIpipcridin-4-yloxy) pyrimidin-4-yI] -4,6- dihydropyrrolo [3,4-c]pyrazole. Example 15
Preparation of 3-(thien-2-yl)-carboxamido-S-[2-(4-methyI-piρerazin-4- yl)pyrimidin-4-yl]-4,6-dihydropyrrolo[3,4-c]pyrazole.
A suspension of 3-(thien-2-yl)-carboxamido-5-[(2-chloro)-pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole (0.25 g, 0.6 mmol), 4-methyl piperazine (0.5 ml, 4.78 mmol) in iso-propanol (4 ml) was placed in a microwave oven for 45 minutes at 160°C. After evaporation ofthe solvents, the mixture was taken up in dichloromethane (50 ml), washed with water (2 X 100 ml), brine, dried over sodium sulfate, filtered and dried under vacuum. The crude material was purified by flash chromatography on silica gel, using dichloromethane: methanol: ammonium hydroxide 95:5:0.5, to yield the title compound (0.115 g, 50%) as a beige powder.
IH-NMR (400 MHz, DMSO-56) ppm: 12.47 (s,bs,lH), 11.03 (s,bs,lH ), 8.13 (m,lH),
7.91 (m,2H), 7.87 (m,lH), 7.22 (m,lH), 5.89 (m,lH), 4.63 (m,4H), 3.72 (m,4H), 2.28
(m,4H), 2.24 (s,3H).
[M+H]+ 411.16; r.t. 2.450 min
By operating in an analogous way and by using the suitable amine, the following compounds of Table I were prepared:
Table I
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
Example 16 Preparation of 3-[(4-tcrt-buryI-bcnzamido)-5-pyrimidin-2-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole A solution of 3-(4-tert-butyl-benzamido)-l-emoxycarbonyl-4,6-dihydroρyrrolo[3,4- c]pyrazole (50 mg, 0.14 mmol) in DMF (3 ml), was treated with 2-chloro-pyrimidine (32 mg, 0.28 mmol) and K2C03 (0.21 mmol). The reaction mixture was stirred for 8 hours at 50°C. Methanol (5 ml) was then added to the mixture and the solution was stirred for 1 hour at room temperature. The solvent was evaporated and the solution was washed with water and the organic product was extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over sodium sulfate, filtered and dried under vacuum. The crude material was purified by flash chromatography on siUca gel, using cyclohexane:ethyl acetate as eluent to yield the title compound as a colorless solid (yield 50%). By operating in an analogous way, the following compound was also obtained:
3-[(2-naphthylacetamido)-5-pyrimidin-2-yl]-4,6-dihydropyrrolo[3,4-c]pyrazole IH-NMR (400 MHz, DMSO-56) ppm: 12.55-11.93 (m, IH), 10.72 (bs, IH), 8.39-8.31 (d, 2H, J=4.88 Hz), 7.91-7.83 (m, 3H), 7.80 (s, IH), 7.54-7.38 ( , 3H), 6.69-6.59 (t, IH, J=4.88 Hz), 4.55 (m, 4H), 3.79 (s, 2H). Example 17 Preparation of 3-(4-flnoro-ben_zamido)-5-(thiazol-2yl)-4,6-dihydropyrroIo[3,4- cjpyrasole
2-Bromo-thiazole (0.28 ml, 3.12 mmol) was added dropwise to a suspension of 3-(4- fluoro-benzamido)-l-ethoxycarbonyl-4,6-dihydropyrrolo[3,4-c]pyrazole (2.4 mmol) and K2C03 (828 mg, 6 mmol), in DMSO (3 ml).
The reaction mixture was stirred at 100°C for 48 hours. The solution was washed with water and the organic product was extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over sodium sulfate, filtered and dried under vacuum. The crude material was purified by flash chromatography on silica gel, using cyclohexane:ethyl acetate as eluent to yield the title compound.
By operating in an analogous way, the following compounds were also obtained: 3-(4-fluoro-benzamido)-5-(benzothiazol-2yI)-4,6-dihydropyrrolo[3,4-c]ρyrazole; 3-(4-fluoro-benzamido) -S-[6-chloro-(pyrimidin-4-yl)]-4,6-dihydropyrroIo[3,4- c]pyrazoIe IH-NMR (400 MHz, DMSO-δ6) ppm: 12.54 (m, IH), 11.01 (m, IH), 8.41 (s, IH), 8.27-7.90 (m, 2H), 7.61-7.14 (m, 2H), 6.83-6.57 (m, IH), 5.04-4.29 (m, 4H).
Example 18 Preparation of 3-amino-5-tert-bntyloxycarbonyH-ethoxycarbonyl-pyrazolo [4,3- c] 4,5,6,7-tetrahydropyridine. To a solution of 3-amino-5-tert-butyloxycarbonyl-pyrazolo[4,3-c]4,5,6,7-tetrahydro pyridine (94.1 g, 0.395 moles) and N,N-diisopropylethylamine (135 ml, 0.79 moles) in tetrahydrofuran (1700 ml), ethylchlorformate (98% assay, 37.6 ml, 0.395 moles) in tetrahydrofuran (300 ml) was added dropwise at 0°C in 75 minutes. The mixture was stirred at 0CC for 30 minutes then evaporated under vacuum. The residue was taken-up with water (1000 ml) and extracted with ethyl acetate (3 x 800 ml). The combined organic extracts were washed with brine (500 ml), dried over sodium sulfate, and evaporated to dryness. The crude mixture (144.5 g) was purified by flash- chromatography on silica gel employing CH2C12/ EtOAc as eluent 87:13 to 1:1, to give the title compound as a colorless solid (29 g, yield 24%, HPLC Λ% = 98.6) and the regioisomer 3-amino-5-tert-butyloxycarbonyl-2-ethoxycarbonyl-ρyrazolo[4,3-c]4,5,6,7- telrahydropyridine (62 g, yield 50%, HPLC Λ%= 99). IH-NMR (400 MHz, DMSO-56) ppm: 10.06 (s, broad signal, 2H), 4.3-4.2 (m, 4H), 3.6 (m, 2H), 2.6 (m, 2H), 1.27 (t, 3H) 1 (2, 9H).
Example 19 Preparation of S-amino-l-ethosycarbonyl- 4,6-pyrazolβ[4,3-e] 4,5,6,7- tetrahydropyridine
A solution of HCl 4M in dioxane (23 ml) was added to a solution of 3-amino-5-tert- butyloxycarbonyl- 1 -ethoxycarbonyl-pyrazolo[4,3 -c]4,5,6,7-tetrahydroρyridine (3.5 g, 0.011 mol); the white suspension was stirred at room temperature for 8 hours. The solid was filtered and washed with Et20. The title compound was obtained as a colorless powder (2.7 g, yield 100%) and was used without any further purification.
Example 20 Preparation of 3-amino-l-ethoxycarbonyl-5-[(2-methyIthio)pyrimidin-4-yl]- 4,6- pyrazolo [4,3-c] 4,5,6,7-tetrahydropyridine 2-Methylthio-4-chloropyrimidine (1.54 ml, 0.013 mol) and K2C03 (3.3 g, 0.024 mol) were added to a solution of 3-am__no-l-ethoxycarbonyl-4,6-ρyrazolo[4,3-c]4,5,6,7- tetrahydro pyridine in DMSO (50 ml). The mixture was heated at 90°C for 4 hours. Water (30 ml) was added and the mixture was extracted with ethyl acetate (2 x 20 ml). The organic layers were combined, washed with brine, dried over sodium sulfate, filtered and dried under vacuum. The crude material was purified by flash chromatography on silica gel, using cyclohexane:ethyl acetate as eluent to yield the title compound as a colorless solid (2.7 g, yield 82%).
IH-NMR (400 MHz, DMSO-56) ppm: 8.19-7.98 (m, IH), 6.77-6.46 (m, IH), 5.83-5.18 (m, 2H), 4.68-4.20 (m, 4H), 4.04-3.74 (m, 2H), 3.04-2.86 (m, 2H), 2.47 (s, 3H), 1.32- 1.27 (t, 3H, J=7.07Hz). Example 21
Preparation of 3-(tert-butyl-benzamido)-l-ethoxycarbonyl-5-[(2- methylthio)pyrimidin-4-yl]-4,6-pyrazoIo [4,3-c]4,5,6,7-tetrahydro pyridine Tri-(2-aminoethyl)-amine polystirene (4 g, 13 mmol) was added to a solution of 3- amino-l-ethoxycarbonyl-5-[(2-mefhylthio)pyrimidin-4-yl]-4,6-pyrazolo[4,3-c]4,5,6,7- tetiahydropyridine (860 mg, 2.6 mmol) in dry THF (30 ml). 4-Tert-butyl benzoyl chloride (0.85 ml, 4.16 mmol) was added dropwise to the suspension. The mixture was stirred at room temperature for 8 hours. The suspension was filtered, then water was added and the mixture was extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over sodium sulfate, filtered and dried under vacuum. The crude material was purified by flash chromatography on silica gel, using cyclohexane:ethyl acetate as eluent to yield the title compound as a yellow oil (700 mg, 55%).
By operating in an analogous way the foUowing compounds were also obtained using the suitable acyl chloride derivative: 3-(4-fluorobenzamido)-l-ethoxycarbonyI-5-[(2-methylthio)pyrimidin-4-yI]-4,6- pyrazolo [4,3-c]4,5,6,7-tetrahydro pyridine (yield 68%);
3-(3-pheπoxy-benzamido)-l-ethoxycarbonyl-5-[(2-methylthio)pyrimidin-4-yl]-4,6- pyrazolo [4,3-c]4,5,6,7-tetrahydro pyridine (yield 72%);
Example 22 Preparation of 3-(tert-butyl-bcnzamido)-5-[(2-mcthylthio)pyrimidin-4-yI]-4,6- pyrazolo [4,3-c]4,5,6,7-tetrahydropyridine
A solution of 3-(te__t-butyl-benzamido)-l-emoxycarbonyl-5-[(2-methylt__ύo)ρyιimidin-4- yl]-4,6-pyrazolo[4,3-c]-4,5,6,7-tetrahydropyridine (700 mg, 1.42 mmol) in MeOH (15 ml) and tiiethylamine (1 ml), was stirred at room temperature for 4 hours. After evaporation of the solvent, the solid was washed with diethyl ether and dried, affording the title compound (600 mg, yield 100%).
IH-NMR (400 MHz, DMSO-56) ppm: 12.34(m, IH), 10.43(m5lH), 8.08-8.01 (d, IH, J=6.10Hz), 8.00-7.92 (d,2H, J=8.42Hz), 7.61-7.46 (m, 2H), 6.68-6.44 (m, IH), 4.73- 4.42 ( , 2H), 4.15-3.77 (m, 2H), 2.85-2.70 (m, 2H), 2.44 (s, 3H), 1.34 (s, 9H). By operating in an analogous way, the following compounds were also obtained: 3-(4-fluorobeπzamido)-5-[(2-methylthio)pyrimidin-4-yI]-4,6-pyrazoIo[4 -c]4,5,6,7- tetrahydropyridine
IH-NMR (400 MHz, DMSO-56) ppm: 12.36(m, IH), 10.55(m,lH), 8.15-8.07 (m, 2H), 8.07-8.02 (d, IH, J=6.10Hz), 7.41-7.32 (m, 2H), 6.65-6.56 (d, IH, J=6.10Hz), 4.64- 4.47 (m, 2H), 4.08-3.91 (m, 2H), 2.83-2.72 (m, 2H), 2.44 (s, 3H); 3-(3-phenoxy-benzamido)-S-[(2-methylthio)pyrimidin-4-yl]-4,6-pyrazoIo[4,3- c] 4,5,6,7-tetrahydropyridine IH-NMR (400 MHz, DMSO-56) ppm: 12.35(m, IH), 10.56(m,lH), 8.06-8.01 (d, IH, J=6.22 Hz), 7.86-7.79 (d, IH, J=8.05Hz), 7.64 (s, IH), 7.58-7.52 (t, IH, J=8.05 Hz), 7.49-7.41 (m, 2H), 7.28-7.18 (m, 2H), 7.13-7.06 (m, 2H), 6.65-6.53 (d, IH, J=6.20Hz), 4.61-4.46 (m, 2H), 4.03-3.90 (m, 2H), 2.82-2.71 (m, 2H), 2.42 (s, 3H). Example 23
Preparation of 3-(4-tert-butyl-ben_zamido)-l-poIy§tyrenetrityl-5-[(2- methylthio)pyrimidin-4-yl]-pyra_zolo[4,3-c]4,5,6,7-tetrahydropyridine
Trityl chloride resin (1 g, loading 1.27 mmol/g) was sweUed with 3 ml of dichloromethane. A solution of 3-(tert-butyl-beι__zantido)-5-[(2-methyltMo)py__iιmd__n-4- yl]-4,6-pyrazolo[4,3-]4,5,6,7-tetrahydropyridine (530 mg, 1.25 mmol) in 10 ml of dimethylformamide was added.
The mixture was stirred at room temperature for 24 hours. After filtration, the resin was washed with dichloromethane (2 x 20 ml), MeOH (2 x 20 ml), dimethylformamide (2 x 20 ml), dichloromethane (3 x 20 ml) and diethyl ether (2 x 20 ml). The resin was dried under vacuum yielding the title compound (1.21 g, loading 50%). By operating in an analogous way, the following compounds were also obtained: 3-(4-fluoro-benzamido)-l-polystyrenetrityl-5-[(2-methyIthio)pyrimidin-4-yl]- pyrazoIo[4,3-c]4,5,6,7-tetrahydro pyridine (loading 73%); 3-(3-phenoxy-benzamido)-l-polystyrenetrityl-5-[(2-methyIthio)pyrimidin-4-yl]- pyrazolo [4,3-c] 4,5,6,7-tetrahydro pyridine (loading 42%).
Example 24 Preparation of 3-(4-tert-butyl-benzamido)-l-poIysryrenetriryl-5-[(2- methanesuIfonyl)pyrimidin-4-yI]-pyrazolo[4,3-c]4,5,6,7-tetrahydropyridine A solution of m-chloroperbenzoic acid and NaOH (1/1) was added dropwise to a solution of 3-(4-tert-bu1yl-ber_zamido)-l-polys1yrenetri1yl-5-[(2-methylt__uo)pyriinidin-4- yl]-pyrazolo[4,3-c]4,5,6,7-tetrahydropyridine in dioxane. The mixture was stirred for 1 hour at room temperature. After filtration, the resin was washed with dichloromethane (2 x 20 ml), MeOH (2 x 20 ml), dimethylformamide (2 x 20 ml) dichloromethane (3 x 20 ml) and diethyl ether (2 x 20 ml) and was dried under vacuum yielding the title compound.
By operating in an analogous way, the following compounds may be also obtained: 3-(4-fluoro-ben__jamido)-l-poIystyrenetrityl-5-[(2-methanesulfonyl)pyrimidin-4-yl]- pyrazolo[4,3-c]4,5,6,7-tetrahydropyridine;
3-(3-pheno_^-ben2amido)-l-poIystyreneWtyI-5-[(2-methane§ulfonyl)pyrimid__n-4- yI]-pyrazoIo[4,3-c]4,5,β,7-tetrahydropyridine. Example 25
Preparation of 3-(4-tert-butyl-benzamido)-l-poIystyrenetrityl-5-[(2- propyIammo)p3nrimidm-4-yI]-pyrazolo[4,3-c]4,5,6,7-tetrahydropyridine
Propylamine (30 eq) was added to a suspension of 3-(4-tert-butyl-benzamido)-l- polystyrenetrityl-5-[(2-methanesulfonyl)pyrintidin-4-yl]-pyrazolo[4,3-c]4,5,6,7- tetiahydropyridine in dioxane. The mixture was stirred for 20 hours at 80°C. After filtration, the resin was washed with dichloromethane (2 x 20 ml), MeOH (2 x 20 ml), dimethylformamide (2 x 20 ml) dichloromethane (3 x 20 ml) and diethyl ether (2 x 20 ml). The resin was dried under vacuum affording the title compound.
By operating in an analogous way, the foUowing compounds may be also obtained: 3-(4-tert-butyl-benzamido)-l-polystyrenetrityI-5-[(2-benzylamino)pyrimidin-4-yl]- pyrazolo [4,3-c] 4,5,6,7-tetrahydropyridine;
3-(4-tert-butyI-benzamido)-l-polystyrenetrityl-5-[(2-N-morphoIino)pyrimidin-4- yl]-pyrazolo[4,3-c]4,5,6,7-tetrahydropyridine;
3-(4-fluoro-benzamido)-l-polystyrenetrityl-5-[(2-propylamino)pyrimidin-4-yl]- pyrazoIo[4,3-c]4,5,6,7-tetrahydropyridinc;
3-(3-phenoxy-bcnzamido)-l-poIystyrenctrityI-5-[(2-propylamino)pyrimidin-4-yl]- pyrazoIo[4,3-c]4,5,6,7-tetrahydropyridine;
3-(4-fluoro-benzamido)-l-polystyrcnetri<yl-5-[(2-benzylamino)pyrimidin-4-yl]- pyrazoIo[4,3-c]4,5,6,7-tetrahydroρyridine; 3-(3-phenoxy-benzamido)-l-poIystyrenetrityI-5-[(2-benzyIamino)pyrimidin-4-yl]- pyrazolo[4,3-c]4,5,6,7-tetrahydropyridine;
3-(4-fluoro-benzan_udo)-l-polystyrenetrityl-5-[(2-N-morρho__ino)pyrimidin-4-yl]- pyrazolo[4,3-c]4,5,6,7-tetrahydropyridine;
3-(3-phcnoxy-bcnzamido)-l-polystyrenctrityl-5-[(2-N-morpholino)ρyrinιid__n-4-yl]- pyra_2olo[4,3-c]4,5,6,7-tetrahydropyridinc.
Example 26 Preparation of 3-(tert-butyl-ben_zamido)-5-[(2-ρropylam__no)pyrimidin-4-yl]-4,6- pyrazolo[4,3-c]4,5,6,7-tetrahydr© pyridine
Λ solution of trifluoroacetic acid in dichloromethane (20/80) was added to the resin 3-(4- tert-bu1yl-benzamido)-l-polystyrenetrityl-5-[(2-propylammo)ρyrimidin-4-yl]- pyrazolo[4,3-c]4,5,6,7-tetrahydroρyridine. The suspension was stirred for 15 minutes at room temperature.
After filtration, the solution was neutralized with saturated NaHC03 and after addition of ethyl acetate the organic phase was separated and evaporated. The colorless solid was washed with diethyl ether and dried under vacuum, thus affording the title compound. IH-NMR (400 MHz, DMSO-56) ppm: 12.16(m, IH), 10.44(m,lH), 8.02-7.93 (d, 2H, J=8.41Hz), 7.83-7.76 (d, IH, J=5.85Hz), 7.58-7.51 (m, 2H), 6.56-6.39 (m, IH), 6.08- 6.01 (d, IH, J=5.97Hz), 4.53-4.44 (m, 2H), 3.94-3.81 (m, 2H), 3.20-3.09 (m, 2H), 2.79- 2.69 (m, 2H), 1.54-1.40 (m, 2H), 1.34 (s, 9H), 0.90-0.76 (t, 3H, J=7.32 Hz). By operating in an analogous way, the following compounds were also obtained: 3-(4-fluoro-benzamido)-5-[(2-propylamino)pyrimidin-4-yl]-pyrazolo[4,3-c]4,5,6,7- tetrahydropyridine
IH-NMR (400 MHz, DMSO-56) ppm: 12.10 (m, IH), 10.53 (bs, IH), 8.20-8.03 (m, 2H), 7.90-7.69 (d, IH, J=5.97 Hz), 7.45-7.24 (m, 2H), 6.50 (bs, IH), 6.19-5.88 (d, IH, J=5.97 Hz), 4.48 (bs, 2H), 4.08-3.73 (m, 2H), 3.30-2.96 (m, 2H), 2.87-2.62 (m, 2H), 1.65-1.37 ( , 2H), 1.01-0.64 (t, 3H, J=7.32 Hz);
3-(3-phenoxy-bcnzamido)-5- 2-propylanι_ oo)ρyrimidin-4-yl]-pyrazoIo[4^- c] 4,5,6,7-tetrahydropyridine
IH-NMR (400 MHz, DMSO-56) ppm: 12.33(bs, IH), 10.56(bs,lH), 7.86-7.78 (m, 2H), 7.65 (s, IH), 7.58-7.52 (m, IH), 7.48-7.41 (m, 2H), 7.29-7.23 (m, IH), 7.23-7.17 (m, IH), 7.12-7.05 (m, 2H), 6.96-6.73 (m, IH), 6.25-6.10 (d, IH, J=5.98Hz), 4.61-4.44 (m, 2H), 4.02-3.83 (m, 2H), 3.22-3.11 (m, IS), 2.81-2.67 (m, 2H), 1.57-1.41 (m, 2H), 0.89- 0.76 (t, 3H, J=7.08Hz);
3-(tert-buty- benzamido)-5-[(2-morρholino)pyrimidin-4-yl]-4,6-ρyrazolo[4^- c] 4,5,6,7-tetrahydropyridine; 3-(4-fluoroben2amido)-5-[(2-morρhoUno)ρyrimidin-4-yl]-4,6-pyraz_oIo[4,3- c] 4,5,6,7-tetrahydropyridine IH-NMR (400 MHz, DMSO-56) ppm: 12.32(bs, IH), 10.51(bs,lH), 8.14-8.06 (m, 2H), 7.93-7.88 (d, IH, J=5.98 Hz), 7.40-7.32 (t, 2H, J=8.78 Hz), 6.27-6.06 (d, IH, J=5.85 Hz), 4.59-4.37 (m, 2H), 4.01-3.87 (m, 2H), 3.72-3.55 (m, 8H), 2.82-2.65 (m, 2H); 3-(3-pheno___y-ben_2amido)-5-[(2-iHo_rpholino)pyrimidin-4-yl]-4,6-pyrasolo[4^- c] 4,5,6,7-tetrahydropyridine
IH-NMR (400 MHz, DMSO-56) ppm: 12.32(bs, IH), 10.53(bs,lH), 7.92-7.88 (d, IH, J=6.09Hz), 7.84-7.79 (d, IH, J=7.68Hz), 7.63 (bs, IH), 7.58-7.52 (t, IH, J=7.92Hz), 7.48-7.41 (m, 2H), 7.28-7.17 (m, 2H), 7.13-7.06 (m, 2H), 6.31-6.04 (d, IH, J=5.61Hz), 4.58-4.39 ( , 2H), 4.01-3.86 (m, 2H), 3.70-3.56 (m, 8H), 2.80-2.66 (m, 2H); 3-(tert-butyl-ben_zamido)-5-[(2-benzylamino)pyrimidin-4-yl]-4,6-pyrazolo[4,3- c]4,S,6,7-tetrahydropyridine
IH-NMR (400 MHz, DMSO-56) ppm: 12.26(m, IH), 10.42(bs,lH), 8.04-7.95 (d, 2H, J=8.54 Hz), 7.82-7.76 (d, IH, J=5.97 Hz), 7.57-7.50 (d, 2H, J=8.54 Hz), 7.32-7.03 (m, 6H), 6.14-6.99 (m, IH), 4.53-4.36 (m, 4H), 3.92-3.78 (m, 2H), 2.77-2.58 (m, 2H), 1.33 (s, 9H);
3-(4-fluoro benzamido)-5-[(2-bcnzylamino)pyrimidin-4-yl]-4,6-pyraz»lo[4^- c] 4,5,6,7-tetrahydropyridine
IH-NMR (400 MHz, DMSO-56) ppm: 12.29(bs, IH), 10.54(bs,lH), 8.17-8.08 (m, 2H), 7.82-7.76 (d, IH, J=5.97 Hz), 7.40-7.32 (m, 2H), 7.31-7.06 (m, 6H), 6.14-6.02 (d, IH, J=5.97 Hz), 4.52-4.35 (m, 4H), 3.94-3.76 (m, 2H), 2.77-2.59 (m, 2H);
3-(3-phenoxy-benzamido)-5-[(2-benzylamino)pyrimidin-4-yl]-4,6-pyrazolo[4,3- c]4,5,6,7-tetrahydropyridine
IH-NMR (400 MHz, DMSO-56) ppm: 12.31(bs, IH), 10.57(bs,lH), 7.88-7.82 (m, IH),
7.82-7.78 (d, IH, J=6.22 Hz), 7.68 (bs, IH), 7.59-7.51 (m, IH), 7.47-7.39 (m, 2H), 7.34-7.13 (m, 7H), 7.11-7.03 (d, 2H, J=7.80 Hz), 6.25-6.05 (d, IH, J=6.22 ), 4.54-4.46 (m, 2H), 4.44-4.37 (d, 2H, J=6.10 Hz), 3.93-3.81 (m, 2H), 2.74-2.62 (m, 2H); l-ethoxycarbonyl-3-(4-fluoro-bcnzamido)-5-[(2-mcthancsulfonyl)pyrimidin-4-yl]- 4,6-dihydropyrrolo[3,4-c]pyrazole IH-NMR (400 MHz, DMSO-56) ppm: 11.66 (m, IH), 8.47-8.33 (dd, IH, J=5.86Hz, J=2.20Hz), 8.28-8.09 ( , 2H), 7.46-7.30 (m, 2H), 6.99-6.82 (m, IH), 5.04-4.75 (m, 4H), 4.57-4.36 (m, 2H), 3.34 (s, 3H), 1.48-1.32 (m, 3H).

Claims

CLAIMS 1. A method for treating diseases caused by and/or associated with aa altered protein Idnase activity which comprises administering to a mammal in need thereof an effective amount of a pyrazole represented by formula (I)
Figure imgf000055_0001
wherein
R is a hydrogen atom or a group selected from -COR', -COOR', -CONHR',
-C(=NH)NHR', -S02R' or -SOjNR'R";
Ri is an optionally substituted 5 or 6 membered heterocyclic group with ftom 1 to 3 heteroatoms or heteroatomic groups selected from N, NR', O or S, optionally benzocondensed;
R2 is hydrogen or it is selected from the group consisting of R', -COR', -COOR',
-CONR'R" or -S(0)qR';
R3 and 4 are both hydrogen atoms or methyl groups or, together with the carbon atom to which they are attached, form a cyclopropyl group;
R' and R" are, the same or different and independently in each of he above occasions, a hydrogen atom or an optionaUy substituted group selected from straight or branched
Cι-C6 alkyl, C3-C6 cycloalkyl, aryl, aryl Cι-C6 alkyl, heterocyclyl or heterocyclyl C1-G5 alkyl; m and n are O or l, provided that they are not both 1 ; q is 0 or an integer from 1 to 2; and the pharmaceuticaUy acceptable salts thereof.
2. The method of claim 1 wherein the disease caused by and/or associated with an altered protein kinase activity is a cell proUferative disorder selected from the group consisting of cancer, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.
3. The method of claim 2 wherein the cancer is selected from carcinoma, squamous ceU carcinoma, hematopoietic tumors of lymphoid or myeloid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system, melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid foUicular cancer and Kaposi's sarcoma,
4. The method of claim 1 wherein the cell proliferative disorder is selected from benign prostate hyperplasia, fømitial adenomatosis, polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proUferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis. 5. The method of claim 1 which provides tumor angiogenesis and metastasis inhibition.
6. The method of claim 1 further comprising subjecting the mammal in need thereof to a radiation therapy or chemotherapy regimen in combination with at least one cytostatic or cytotoxic agent. 7. The method of claim 1 wherein the mammal in need thereof is a human.
8. A method for inhibiting protein kinase activity which comprises contacting the said kinase with an effective amount of a compound of formula (I) as defined in claim 1.
9. A pyrazole represented by formula (I)
Figure imgf000056_0001
wherein
R is a hydrogen atom or a group selected from -COR', -COOR', -CONHR',
-C(=NH)NHR', -S02R' or -SO.-NRR";
Ri is an optionally substituted 5 or 6 membered heterocyclic group with from 1 to 3 heteroatoms or heteroatomic groups selected from N, NR', O or S, optionally benzocondensed;
R2 is hydrogen or it is selected from the group consisting of R', -COR', -COOR', -CONR'R" or -S(0)qR';
R3 and R are both hydrogen atoms or methyl groups or, together with the carbon atom to which they are attached, form a cyclopropyl group;
R' and R" are, the same or different and independently in each ofthe above occasions, a hydrogen atom or an optionaUy substituted group selected from straight or branched Cι-C6 alkyl, C3-C6 cycloalkyl, aryl, aryl Ci-Cβ alkyl, heterocyclyl or heterocyclyl Cι-C6 alkyl; m and π are 0 or 1, provided that they are not both 1 ; q is 0 or an integer from 1 to 2; and the pharmaceutically acceptable salts thereof.
10. A compound of formula (I) according to claim 9 wherein R2 is hydrogen or a group -COOR' and R' is a straight or branched Cι-C6 alkyl group.
11. A compound of formula (I) according to claim 10 wherein R' is ethyl.
12. A compound of formula (I) according to claim 9 wherein ] is an optionaUy substituted heterocycle selected from pyrimidine, thiazole or benzothiazole.
13. A compound of formula (I) according to claim 12 wherein Ri is a pyrimidine ring optionally substituted by one or more groups selected from halogen, heterocycles, alkylheterocycles, hydroxyalkylheterocycles, alkoxy, heterocyclyloxy, alkylheterocyclyloxy, alkylthio, alkylsulfonyl, alkylamino, cycloalkylamino, arylamino and arylaltylamino.
14. A compound of formula (I) according to claim 9 wherein m is 0 or 1 and n is 0.
15. A compound of formula (I) according to claim 9 wherein Ri, R' and R" are optionaUy substituted, in any of their free positions, by one or more groups selected from: halogen, nitro, oxo groups (=0), carboxy, cyano, alkyl, polyfluorinated alkyl, hydroxyalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, amino groups and derivatives thereof such as aminoalkyl, al-kylaminoalkyl, dialkylammoalkyl, alkylamino, dialkylamino, cycloa__kylamino, aiylamino, diarylamino, a__yla_l_kylamino, ureido, alkylureido or arylureido; carbonylamino groups and derivatives thereof such as formylamino, alkylcarbonylamino, alkenylcarbonylamino, aiylcarbonylamino, alkoxycarbonylamino; hydroxy groups and derivatives thereof such as allcoxy, aryloxy, aiylalkyloxy, heterocyclyloxy, alkylcarbonyloxy, arylcarbonyloxy, cyclαalkenyloxy or aϋcylidenβaminooxy; carbonyl groups and derivatives thereof such as alkylcarbonyl, arylcarbonyl, aUcoxycarbonyl, aryloxycarbonyl, cycloalkyloxycarbonyl, aminocarbonyl, aUcylaminβcarbonyl, diallsylaminocarbonyl; sulfurated derivatives such as alkylthio, arylthio, alkylsulfonyl, arylsulfonyl, alkylsulfinyl, arylsulfinyl, arylsulfonyloxy, aminosulfonyl, alkylaminosulfonyl or dialltylaminosulfonyl.
16. A compound of formula (I) as defined in claim 9, optionaUy in the form of a pharmaceutically acceptable salt, selected from the group consisting of:
I . 3-amino- 1 -ethoxycarbonyl-5-[(2-methyltMo)ρyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]ρyrazole, 2. l-ethoxycarbonyl-3-(4-fluoro-ber_zamido)-5-[(2-methylMo)pyrin_ιidin-4-yl]- 4 ,6- dihydroρyιτolo[3,4-c]pyrazole,
3. 3 -(4-tert-butyl-benzamido)- 1 -ethoxycarbonyl-5 -[(2 -metiιylMo)pyιimidin-4-yl]- 4,6-dihydropyrrolo[3,4-c]pyrazole,
4. l-ethoxycarbonyl-3-(3-phenoxy-benzamido)-5-[(2-methyltWo)py_mιidin-4-yl]- 4,6-dihydropyrrolo[3,4-c]pyrazole,
5. 3-(4-fluoro-benzamido)-5-[(2-propylammo)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole,
6. 3-(4-tert-butyl-benza_mido)-5-[(2-ρropylammo)ρyrimidin-4-yl]-4,6- d__hydropyrrolo[3,4-c]pyrazole,
7. 3-(3-ρhenoxy-benzamido)-5-[(2-propylam__no)ρyrimidin-4-yl]-4,6- dihydropyrrolo[3 ,4-c]pyrazole,
8. 3-(4-fluoro-benzamido)-5-[(2-benzylammo)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole,
9. 3-(4-tert-butyl-benzamido)-5-[(2-benzylamino)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole,
10. 3-(3-phenoxy-benzamido)-5-[(2-benzylan_ι_mo)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole,
II. 3-(4-fluoro-benzamido)-5-[2-(N-mo holino)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole,
12. 3-(4-tert-butyl-benzamido)-5-[2-(N-moφhoh^o)py)±nidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole,
13. 3-(3-phenoxy-benzamido)-5-[2-(N-moφholino)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole,
14. 3-(4-fluoro-benzamido)-5-[2-(4-memyl-piperazino)pyrimidin-4-yl]-4,6- dihydroρyrrolo[3,4-c]pyrazole,
15. 3-(4-tert-butyl-benzamioώ)-5-[2-(4-me1hyl-piperaz__no)pyrirmdin-4-yl]-4,6- dihydropyrroloβ ,4-c]pyrazole,
16. 3-(3-phenoxy-benzamido)-5-[2-(4-methyl-ρiperazino)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole,
17. 3-(4-fluoro-benzamido)-5-[2-(4-methyl-piperichno)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyra_zole,
18. 3-(4-tert-butyl-benzantido)-5-[2-(4-methyl-piperidino)ρyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole, 19. 3-(3-phenoxy-benzan_ndo)-5-[2-(4-memyl-ρiρeridmo)pyrimidin-4-yl]-4,6- dihydroρyrrolo[3,4-c]pyrazole, 20. 3-(4-fluoro-benzamido)-5-[2-(4-dime1hyl-ethylendiammo)py__imidin-4-yl]-4,6- dihydropyιrolo[3,4-c]pyrazole, 21. 3-(4-tert-butyl-benzamido)-5-[2-(4-d__memyl-ethylendiamino)pyrimidin-4-yl]-4,6- dihydropyrrolo[3 ,4-c]pyrazole, 22. 3-(3-phenoxy-beι__zan_ndo)-5-[2-(4-dimethyl-eftylendiam__no)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole,
23. 3-(4-fluoro-ber_zamido)-5-[2-(l,4,4-trimethyl-emylenώ'ammo)ρyrimidin-4-yl]- 4,6-dihydropyrrolo[3,4-c]pyrazole,
24. 3-(4-tert-bufyl-benzamido)-5-[2-(l,4,4-1rimethyl-ethylendiammo)pyriπtidin-4-yl]- 4,6-dihydropyrrolo[3,4-c]pyrazole, 25. 3-(3-phenoxy-benzanύdo)-5-[2-(l,4,4-trimemyl-ethylendiammo)pyrimidin-4-yl]-
4,6-dihydropyrrolo[3,4-c]pyrazole, 26. 3-(4-fluoro-benzamido)-5-[2-(4-hy(hoxyme1hyl-piperidino)pyrimidin-4-yl]-4,6- dihydroρyrrolo[3,4-c]pyrazole, 27. 3-(4-tert-bu(yl-l)enzamido)-5-[2-(4-hydroxymemyl-piperidino)ρyrimidin-4-yl]- 4,6-dihydropyrrolo[3,4-c]pyrazole,
28. 3-(3-phenoxy-benzamido)-5-[2-(4-hyάϊoxymemyl-piperid o)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole,
29. 3-(4-fluoro-berιzamido)-5-{2-[4-(2-hydroxyethyl)piperaz__no]pyrin_ιidin-4-yl}-4,6- dihydropyrrolo[3,4-c]pyrazole, 30. 3-(4-tert-butyl-ber__zamido)-5-{2-[4-(2-hydroxyemyl)piperazmo]pyrimidin-4-yl}-
4,6-dihydropyrrolo[3,4-c]ρyrazole, 31. 3-(3-phenoxy-benzami(to)-5-{2-[4-(2-hy(_lroxyethyl)piρeraz__no]pyr__n_ddin-4-yl}- 4,6-dihydropyrrolo[3,4-c]pyrazole,
32. 3-(4-fluoro-benzamido)-5-[(2-cyclopropylammo)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole,
33. 3-(4-tert-butyl-benzamido)-5-[(2-cycloproρylammo)pyrimidin-4-yl]-4,6- dihydropyrrolo[3 ,4-c]ρyrazole,
34. 3-(3-phenoxy-benzamido)-5-[(2-cycloρroρyla_mmo)ρyrimidin-4-yl]-4,6- dihydroρyrrolo[3 ,4-c]pyrazole, 35. 3-(4-tert-butyl-benzantido)-5-[(2-ρhenylan_ιmo)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole, 36. 3-(4-fluoro-benzamido)-5-[(2-phenylammo)pyruriidin-4-yl]-4,6- dihyd_ropyrrolo[3,4-c]pyrazole,
37. 3 -(3 -phenoxy-benzamido)-5- [(2-phenylamino)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole,
38. 3-(4-fluoro-benzamido)-5-[(2-ethyloxy)pyrirmdin-4-yl]-4,6-dihydropyrrolo[3,4- c]pyrazole,
39. 3-(4-tert-butyl-benzamido)-5-[(2-ethyloxy)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole, 40. 3-(3-phenoxy-beι__zantido)-5-[(2-ethyloxy)pyrimidin-4-yl]-4,6- dihydropyrrolo [3 ,4-c]pyrazole, 4l. 3-(4-fluoro-benzamido)-5-[2-(l-me1hylpiperidin-4-yloxy)pyrimidin-4-yl]-4,6- dihydropyrrolo[3,4-c]pyrazole, 42. 3-(4-tert-butyl-benzamido)-5-[2-(l-methylpiperidin-4-yloxy)pyrimidin-4-yl]-4,6- dihydrøpyrrolo[3,4-c]pyrazole,
43. 3-(3-pheno3^-benzamido)-5-[2-(l-metiιylpipεridin-4-yloxy)pyr__midin-4-yl]-4,6- dihydroρyrrolo[3,4-c]pyrazole,
44. l-ethoxycarbonyl-3-(2-nφh(alenacetamido)-5-[(2-methyMύo)ρvriιnidin-4-yl]- 4,6-dihydropyιτolo[3,4-c]pyra_?:ole, 45. 3-(4-fluoro-bei__zamido)-5-[6-c oro-(py__inaid -4-yl)]-4)6-dihydropyrrolo[3,4- c]ρyrazole,
46. 3-(4-fluoro-benzamido)-5-(tMazol-2-yl)-4,6-dihydropyrrolo[3,4-c]pyrazole,
47. 3-(4-fluoro-benzamido)-5-(beι__zothiazol-2-yl)-4,6-dihydropyrrolo[3,4-c]pyrazole,
48. 3-(4-tert-butyl-benzamido)-5-| yrirmd__n-2-yl]-4,6-dι^ydropyrrolo[3,4-c]ρyrazole, 49. 3-(2-naρhtølenacetamido)-5-| yrimidin-2-yl]-4,6-dihydropyιrolo[3,4-c]pyrazole5
50. 3-amino- 1 -ethoxycarbonyl-5-[(2-methyltWo)pyrimidin-4-yl]-4,6-pyrazolo[4,3- c]4,5,6,7-tetrahydropyridine,
51. l-ethoxycarbonyl-3-(4-fluoro-benzamido)-5-[(2-methyltMo)pyrimidin-4-yJQ- pyrazolo[4,3-c]4,5,6,7 -tetiahydropyridine, 52. 3-(4-tert-bu1yl-benzamido)-l-e1hoxycarbonyl-5-[(2-memylt_tio)pyrimidin-4-yl]- pyrazolo[4,3-c]4,5,6,7-tetrahydropyridine,
53. l-ethoxycarbonyl-3-(3-phenoxy-benzamido)-5-[(2-methyltMo)pyrimidin-4-yl]- pyrazolo[4,3-c]4,5,6,7-tetiahydropyridine,
54. 3-(4-fluoro-benzamido)-5-[(2-propylam__no)pyrimidin-4-yr|-pyrazolo[4,3- c]4,5,6,7-tetrahydropyridine,
55. 3-(4-tert-bu1yl-benzamido)-5-[(2-propylammo)ρyrin_ud__n-4-yl]-pyrazolo[4,3- c]4,5,6,7-tetrahydropyridine,
56. 3-(3-phenoxy-benzamido)-5-[(2-ρropylammo)ρyrimidin-4-yl]-ρyrazolo[4,3- c]4,5,6,7 -tetiahydropyridine, 57. 3-(4-fluoro-benzamido)-5-[(2-benzylamino)pyri^ c]4,5,6,7-tetrahydropyridine, 58. 3-(4-tert-bu1yl-benzamido)-5-[(2-benzylammo)pyr__π_adin-4-yl]-pyrazolo[4,3- c]4,5,6,7-tetrahydropyridine, 59. 3-(3-phenoxy-benzamido)-5-[(2-ben2ylamino)pyrimidin-4-yl]-ρyrazolo[4,3- c]4,5,6,7-tetrahydropyridine,
60. 3-(4-fluoro-bsnzamido)-5-[(2-N-moφholino)pyr__midin-4-yl]-ρyrazolo[4,3- c]4,5,6,7-tetrahydropyridine,
61. 3-(4-tert-butyl-benzamido)-5-[(2-N-moφholino)pyrimidin-4-yl]-pyrazolo[4,3- c]4,5,6,7-tetrahydropyridine, 62. 3-(3-phenoxy-benzamido)-5-[(2-N-moφholino)pyrin_ύd__n-4-yl]-pyrazolo[4,3- c] ,5,6,7 -tetiahydropyridine. 17. A compound of formula (I) as defined in claim 9, optionally in the form of a pharmaceutically acceptable salt, selected from those reported in the experimental section. 18. A process for preparing the compounds of formula (I) and the pharmaceutically acceptable salts thereof, as defined in claim 9, which process comprises: a) reacting under acidic or basic conditions a compound of formula (IT)
Figure imgf000062_0001
wherein Q represents a suitable nitrogen protecting group and Q' represents R2 or a suitable nitrogen protecting group and wherein R2, R3, 4, m and n are as defined in claim 9; so as to obtain a compound of formula (HI)
Figure imgf000062_0002
b) reacting the compound of formula (HI) with a derivative of formula (TV)
Figure imgf000062_0003
wherein R( is as defined in claim 9 and X represents a halogen atom or a suitable leaving group, so as to obtain a compound of formula (V)
Figure imgf000063_0001
c) reacting the compound of formula (V) with a suitable derivative of formula (VI), (VII), (VIII), (DC), (X) or (XI)
R'COX (VI); R'OCOX (VII); R"NCO (VIII); H2N-C(=NH)NH2 (IX); XS02R' (X); XS02NR'R" (XI) wherein R' and R" are as defined in claim 9 and X is a halogen atom or a suitable leaving group, so as to obtain the corresponding compound of formula (I) below
Figure imgf000063_0002
and, optionally, d) converting it into another compound of formula (I) or into a pharmaceutically acceptable salt thereof.
19. The process of claim 18 wherein, within the compound of formula (II), Q is tert- butoxycarbonyl and Q' is a hydrogen atom or a group R2 of formula -COOR' wherein R' is ethyl.
20. The process of claim 18 wherein the compound of formula (II) is treated under acidic conditions in the presence of trifluoroacetic or hydrochloric acid.
21. The process of claim 18 wherein X is a chlorine atom or a suitable leaving group selected from alkylsulfonyl or aiylsulfonyl.
22. A process for preparing the compounds of formula (I) and the pharmaceuticaUy acceptable salts thereof, as defined in claim 9, which process comprises: e) hydrolyzing under acidic or basic conditions the compound of formula (I) being obtained in step (c) of claim 18 and wherein R, Rj, R3, 4, m and n have the above reported meanings and ' is a suitable pyrazole nitrogen protecting group
Figure imgf000064_0001
and reacting the thus obtained compound bearing a hydrogen atom in place of Q' in the presence of a suitable polymeric resin (P), so as to obtain the resin supported compound of formula (XII)
Figure imgf000064_0002
f) optionally converting the compound of formula (XH) into another compound of formula (XII), and g) cleaving the polymeric resin so as to obtain the desired compound of formula (I) and, whenever desired, converting it into a pharmaceutically acceptable salt thereof.
23. The process of claim 22 wherein, in step (e), the polymeric resin (P) is 2-chloro- trityl chloride resin, trityl chloride resin, p-nitrophenyl carbonate Wang resin or isocyanate polystirenic resin.
24. A library of two or more pyrazole derivatives represented by formula (I)
Figure imgf000064_0003
wherein
R is a hydrogen atom or a group selected from -COR', -COOR', -CONHR',
-C(=NH)NHR', -S02R' or -S02NR'R";
Ri is an optionally substituted 5 or 6 membered heterocyclic group with from 1 to 3 heteroatoms or heteroatomic groups selected from N, NR", O or S, optionally benzocondensed;
R2 is hydrogen or it is selected from the group consisting of R', -COR', -COOR',
-CONR'R" or -S(0),R';
R3 and R» are both hydrogen atoms or methyl groups or, together with the carbon atom to which they are attached, form a cyclopropyl group;
R' and R" are, the same or different and independently in each of he above occasions, a hydrogen atom or an optionaUy substituted group selected from straight or branched
Ci-Cβ alkyl, C3-C6 cycloalkyl, aryl, aryl Ci-Cβ alkyl, heterocyclyl or heterocyclyl Cj- alkyl; m and n are 0 or 1 , provided that they are not both 1 ; q is 0 or an integer from 1 to 2; and the pharmaceutically acceptable salts thereof.
25. A pharmaceutical composition comprising an effective amount of a pyrazole of formula (I) as defined in claim 9 and, at least, one pharmaceutically acceptable excipient, carrier or diluent.
26. A pharmaceutical composition according to claim 25 further comprising one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.
27. A product or kit comprising a compound of formula (1) as defined in claim 9, or a pharmaceutical composition thereof as defined in claim 25, and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.
28. Λ compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 9, for use as a medicament.
29. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 9, in the manufacture of a medicament for treating diseases caused by and/or associated with an altered protein Idnase activity.
30. Use according to claim 29 for the treatment of tumors.
PCT/EP2004/050237 2003-03-11 2004-03-02 Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them WO2004080457A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US10/548,332 US20070037790A1 (en) 2003-03-11 2004-03-02 Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
MXPA05009719A MXPA05009719A (en) 2003-03-11 2004-03-02 Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
EP04716253A EP1608364A1 (en) 2003-03-11 2004-03-02 Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
BRPI0408486-1A BRPI0408486A (en) 2003-03-11 2004-03-02 active bicyclopyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JP2006505439A JP2006519816A (en) 2003-03-11 2004-03-02 Bicyclopyrazole derivatives active as kinase inhibitors, processes for their preparation, and pharmaceutical compositions comprising them
CA002518395A CA2518395A1 (en) 2003-03-11 2004-03-02 Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45388503P 2003-03-11 2003-03-11
US60/453,885 2003-03-11

Publications (1)

Publication Number Publication Date
WO2004080457A1 true WO2004080457A1 (en) 2004-09-23

Family

ID=32990832

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/050237 WO2004080457A1 (en) 2003-03-11 2004-03-02 Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Country Status (7)

Country Link
US (1) US20070037790A1 (en)
EP (1) EP1608364A1 (en)
JP (1) JP2006519816A (en)
BR (1) BRPI0408486A (en)
CA (1) CA2518395A1 (en)
MX (1) MXPA05009719A (en)
WO (1) WO2004080457A1 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006049880A1 (en) * 2004-10-27 2006-05-11 Janssen Pharmaceutica, N.V. Tetrahydro pyridinyl pyrazole cannabinoid modulators
EP1698335A1 (en) * 2003-12-26 2006-09-06 Ono Pharmaceutical Co., Ltd. Preventive and/or therapeutic agent for disease in which mitochondrial benzodiazepine receptor participates
WO2008017465A1 (en) * 2006-08-10 2008-02-14 F. Hoffmann-La Roche Ag Bicyclic lactam derivatives, their manufacture and use as pharmaceutical agents
WO2008125945A2 (en) * 2007-04-12 2008-10-23 Pfizer Inc. 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c
WO2009138440A1 (en) * 2008-05-15 2009-11-19 Nerviano Medical Sciences S.R.L. Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs
US20100087467A1 (en) * 2003-09-23 2010-04-08 Vertex Pharmaceuticals Incorporated Compositions Useful As Inhibitors of Protein Kinases
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2010088050A3 (en) * 2009-01-28 2010-11-25 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
CN102134243A (en) * 2011-03-04 2011-07-27 中国医学科学院医药生物技术研究所 Bicyclic amino pyrazole derivatives with anti-tumor activity
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2485727A2 (en) * 2009-10-06 2012-08-15 Afraxis, Inc. Pyrrolopyrazoles for treating cns disorders
US8278450B2 (en) 2007-04-18 2012-10-02 Takeda Pharmaceutical Company Limited Kinase inhibitors
KR20170077168A (en) 2014-10-31 2017-07-05 우베 고산 가부시키가이샤 Substituted dihydropyrrolopyrazole compound
US9763922B2 (en) 2014-11-27 2017-09-19 Genentech, Inc. Therapeutic compounds and uses thereof
KR20180018661A (en) 2015-06-15 2018-02-21 우베 고산 가부시키가이샤 Substituted dihydropyrrolopyrazole derivatives
US10208052B1 (en) 2017-03-20 2019-02-19 Forma Therapeutics, Inc. Compositions for activating pyruvate kinase
WO2019086142A1 (en) 2017-11-02 2019-05-09 Aicuris Gmbh & Co. Kg Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2020100944A1 (en) 2018-11-14 2020-05-22 宇部興産株式会社 Dihydropyrrolopyrazole derivative
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
US10954233B2 (en) 2016-09-09 2021-03-23 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
US11001588B2 (en) 2018-09-19 2021-05-11 Forma Therapeutics, Inc. Activating pyruvate kinase R and mutants thereof
US11247989B2 (en) 2016-05-24 2022-02-15 Genentech, Inc. Therapeutic compounds and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012242A2 (en) * 2000-08-10 2002-02-14 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81790C2 (en) * 2002-12-19 2008-02-11 Фармация Италия С.П.А. Substituted derivatives of pyrolopyrazol as kinaze inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012242A2 (en) * 2000-08-10 2002-02-14 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642779B2 (en) * 2003-09-23 2014-02-04 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US20100087467A1 (en) * 2003-09-23 2010-04-08 Vertex Pharmaceuticals Incorporated Compositions Useful As Inhibitors of Protein Kinases
EP1698335A1 (en) * 2003-12-26 2006-09-06 Ono Pharmaceutical Co., Ltd. Preventive and/or therapeutic agent for disease in which mitochondrial benzodiazepine receptor participates
EP1698335A4 (en) * 2003-12-26 2007-08-01 Ono Pharmaceutical Co Preventive and/or therapeutic agent for disease in which mitochondrial benzodiazepine receptor participates
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8288536B2 (en) 2004-10-15 2012-10-16 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2005302697B2 (en) * 2004-10-27 2012-09-13 Janssen Pharmaceutica, N.V. Tetrahydro pyridinyl pyrazole cannabinoid modulators
JP2008518008A (en) * 2004-10-27 2008-05-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Tetrahydropyridinylpyrazole cannabinoid modulator
JP4942660B2 (en) * 2004-10-27 2012-05-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Tetrahydropyridinylpyrazole cannabinoid modulator
WO2006049880A1 (en) * 2004-10-27 2006-05-11 Janssen Pharmaceutica, N.V. Tetrahydro pyridinyl pyrazole cannabinoid modulators
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2008017465A1 (en) * 2006-08-10 2008-02-14 F. Hoffmann-La Roche Ag Bicyclic lactam derivatives, their manufacture and use as pharmaceutical agents
WO2008125945A2 (en) * 2007-04-12 2008-10-23 Pfizer Inc. 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c
US8114871B2 (en) 2007-04-12 2012-02-14 Pfizer Inc. 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives
US8999981B2 (en) 2007-04-12 2015-04-07 Pfizer Inc. 3-amido-pyrrolo[3,4-C]pyrazole-5(1H, 4H,6H) carbaldehyde derivatives
WO2008125945A3 (en) * 2007-04-12 2009-03-12 Pfizer 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c
CN104356136A (en) * 2007-04-12 2015-02-18 辉瑞大药厂 Novel 3-amido-pyrrolo[3,4-c]pyrazole-5(1h, 4h.6h) carbaldehyde derivatives
US8278450B2 (en) 2007-04-18 2012-10-02 Takeda Pharmaceutical Company Limited Kinase inhibitors
EA019901B1 (en) * 2008-05-15 2014-07-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs
AU2009248060B2 (en) * 2008-05-15 2013-11-14 Nerviano Medical Sciences S.R.L. Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs
US8809337B2 (en) 2008-05-15 2014-08-19 Nerviano Medical Sciences S.R.L. Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs
WO2009138440A1 (en) * 2008-05-15 2009-11-19 Nerviano Medical Sciences S.R.L. Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs
JP2012516331A (en) * 2009-01-28 2012-07-19 カラ セラピューティクス インコーポレイテッド Bicyclic pyrazoloheterocycles
CN102282147A (en) * 2009-01-28 2011-12-14 卡拉治疗学股份有限公司 Bicyclic pyrazolo-heterocycles
WO2010088050A3 (en) * 2009-01-28 2010-11-25 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
CN102282147B (en) * 2009-01-28 2015-09-30 卡拉治疗学股份有限公司 Bicyclic pyrazolo-heterocycles
EP2485727A2 (en) * 2009-10-06 2012-08-15 Afraxis, Inc. Pyrrolopyrazoles for treating cns disorders
US20120283296A1 (en) * 2009-10-06 2012-11-08 Afraxis, Inc. Pyrrolopyrazoles for treating cns disorders
EP2485727A4 (en) * 2009-10-06 2013-05-01 Afraxis Inc Pyrrolopyrazoles for treating cns disorders
CN102134243A (en) * 2011-03-04 2011-07-27 中国医学科学院医药生物技术研究所 Bicyclic amino pyrazole derivatives with anti-tumor activity
US10968238B2 (en) 2014-10-31 2021-04-06 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole compound
US10131679B2 (en) 2014-10-31 2018-11-20 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole compound
KR20170077168A (en) 2014-10-31 2017-07-05 우베 고산 가부시키가이샤 Substituted dihydropyrrolopyrazole compound
US9763922B2 (en) 2014-11-27 2017-09-19 Genentech, Inc. Therapeutic compounds and uses thereof
US10894798B2 (en) 2015-06-15 2021-01-19 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole derivative
KR20180018661A (en) 2015-06-15 2018-02-21 우베 고산 가부시키가이샤 Substituted dihydropyrrolopyrazole derivatives
US10273252B2 (en) 2015-06-15 2019-04-30 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole derivative
US11247989B2 (en) 2016-05-24 2022-02-15 Genentech, Inc. Therapeutic compounds and uses thereof
US10954233B2 (en) 2016-09-09 2021-03-23 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
US10472371B2 (en) 2017-03-20 2019-11-12 Forma Therapeutics, Inc. Compositions for activating pyruvate kinase
US10836771B2 (en) 2017-03-20 2020-11-17 Forma Therapeutics, Inc. Compositions for activating pyruvate kinase
US11396513B2 (en) 2017-03-20 2022-07-26 Forma Therapeutics, Inc. Compositions for activating pyruvate kinase
US11649242B2 (en) 2017-03-20 2023-05-16 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
US11014927B2 (en) 2017-03-20 2021-05-25 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
US10208052B1 (en) 2017-03-20 2019-02-19 Forma Therapeutics, Inc. Compositions for activating pyruvate kinase
WO2019086142A1 (en) 2017-11-02 2019-05-09 Aicuris Gmbh & Co. Kg Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
US11071725B2 (en) 2018-09-19 2021-07-27 Forma Therapeutics, Inc. Activating pyruvate kinase R
US11001588B2 (en) 2018-09-19 2021-05-11 Forma Therapeutics, Inc. Activating pyruvate kinase R and mutants thereof
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
US11844787B2 (en) 2018-09-19 2023-12-19 Novo Nordisk Health Care Ag Activating pyruvate kinase R
US11980611B2 (en) 2018-09-19 2024-05-14 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
WO2020100944A1 (en) 2018-11-14 2020-05-22 宇部興産株式会社 Dihydropyrrolopyrazole derivative

Also Published As

Publication number Publication date
CA2518395A1 (en) 2004-09-23
EP1608364A1 (en) 2005-12-28
JP2006519816A (en) 2006-08-31
BRPI0408486A (en) 2006-04-04
MXPA05009719A (en) 2005-10-18
US20070037790A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
EP1608364A1 (en) Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JP5925808B2 (en) Tricyclic derivatives, their preparation and their use as kinase inhibitors
EP1660085B1 (en) Pyridylpyrrole derivatives active as kinase inhibitors
US8981092B2 (en) Substituted 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-ones as modulators of protein kinase activity
CA2526578C (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
JP4739761B2 (en) Pyrrolo-pyrazole substituted derivatives as kinase inhibitors
EP2089394B1 (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
EP1309590B1 (en) Azaindole derivatives, process for their preparation, and their use as antitumor agents
JP2005501085A (en) Aminophthalazinone derivatives active as kinase inhibitors, methods of preparing them and pharmaceutical compositions containing them
WO2005005427A1 (en) PYRROLO[3,4-c]PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS
WO2005014572A1 (en) Pyrimidylpyrrole derivatives active as kinase inhibitors
US20070142414A1 (en) N-substituted pyrrolopyridinones active as kinase inhibitors
US7279575B2 (en) Pyrimidylpyrrole derivatives active as kinase inhibitors
JP7233130B2 (en) Novel tricyclic compounds as IRAK4 inhibitors
EP1904503B1 (en) 1h-thieno[2,3-c]-pyrazole compounds useful as kinase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2518395

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/009719

Country of ref document: MX

Ref document number: 2006505439

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004716253

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004716253

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0408486

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2007037790

Country of ref document: US

Ref document number: 10548332

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10548332

Country of ref document: US